U.S. patent application number 13/362542 was filed with the patent office on 2012-11-15 for transgenic mice over-expressing receptor for advanced glycation endproduct (rage) in brain and uses thereof.
This patent application is currently assigned to THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK. Invention is credited to Ann Marie Schmidt, David M. Stern, Shi Du Yan.
Application Number | 20120291145 13/362542 |
Document ID | / |
Family ID | 43805850 |
Filed Date | 2012-11-15 |
United States Patent
Application |
20120291145 |
Kind Code |
A1 |
Stern; David M. ; et
al. |
November 15, 2012 |
TRANSGENIC MICE OVER-EXPRESSING RECEPTOR FOR ADVANCED GLYCATION
ENDPRODUCT (RAGE) IN BRAIN AND USES THEREOF
Abstract
The present invention provides for a transgenic non-human animal
whose cells contain a DNA sequence comprising: (a) a nerve tissue
specific promoter; and (b) a DNA sequence which encodes a receptor
for advanced glycation endproducts (RAGE), wherein the promoter and
the DNA sequence which encodes the receptor for advanced glycation
endproducts (RAGE) are operatively linked to each other and
integrated in the genome of the non-human animal, and wherein said
non-human animal exhibits a reduced amount of cerebral tissue
infarcted following a transient middle cerebral artery occlusion
compared to an identical non-human animal lacking said DNA
sequence.
Inventors: |
Stern; David M.; (Great
Neck, NY) ; Schmidt; Ann Marie; (Franklin Lakes,
NJ) ; Yan; Shi Du; (New York, NY) |
Assignee: |
THE TRUSTEES OF COLUMBIA UNIVERSITY
IN THE CITY OF NEW YORK
|
Family ID: |
43805850 |
Appl. No.: |
13/362542 |
Filed: |
January 31, 2012 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
12908832 |
Oct 20, 2010 |
8124829 |
|
|
13362542 |
|
|
|
|
09638653 |
Aug 14, 2000 |
7919670 |
|
|
12908832 |
|
|
|
|
Current U.S.
Class: |
800/3 ; 435/7.1;
435/7.92; 800/13; 800/14; 800/16; 800/18 |
Current CPC
Class: |
A01K 2227/105 20130101;
A01K 2217/206 20130101; A01K 2217/15 20130101; A01K 67/0275
20130101; A01K 2217/052 20130101; C12N 15/8509 20130101; C07K
14/70503 20130101; A01K 67/0278 20130101; A01K 2267/0356 20130101;
A01K 2267/035 20130101 |
Class at
Publication: |
800/3 ; 800/13;
800/18; 800/16; 800/14; 435/7.1; 435/7.92 |
International
Class: |
A01K 67/027 20060101
A01K067/027; G01N 33/566 20060101 G01N033/566; G01N 21/64 20060101
G01N021/64; A61K 49/00 20060101 A61K049/00 |
Claims
1. A transgenic non-human animal whose cells contain a DNA sequence
comprising: (a) a nerve tissue specific promoter; and (b) a DNA
sequence which encodes a receptor for advanced glycation
endproducts (RAGE), wherein the promoter and the DNA sequence which
encodes the receptor for advanced glycation endproducts (RAGE) are
operatively linked to each other and integrated in the genome of
the non-human animal, and wherein said non-human animal exhibits a
reduced amount of cerebral tissue infarcted following a transient
middle cerebral artery occlusion compared to an identical non-human
animal lacking said DNA sequence.
2. The transgenic non-human animal of claim 1, wherein the promoter
is platelet derived growth factor (PDGF)-B-chain promoter.
3. The transgenic non-human animal of claim 1, wherein the DNA
sequence which encodes amyloid-beta peptide alcohol dehydrogenase
is a human DNA sequence.
4. The transgenic non-human animal of claim 1, wherein the
reduction of infarcted cerebral tissue is about a 50%
reduction.
5. The transgenic non-human animal of claim 1, wherein the
transgenic non-human animal is a mouse, a rat, a sheep, a dog, a
primate, or a reptile.
6. The transgenic non-human animal of claim 1, wherein the
non-human animal is a mammal.
7. A method for evaluating in a non-human transgenic animal the
potential therapeutic effect of an agent for treating Alzheimer's
disease in a human, which comprises: (a) administering an agent to
a transgenic non-human animal whose cells comprise a nerve tissue
specific promoter operatively linked to a DNA sequence which
encodes receptor for advanced glycation endproducts (RAGE); and (b)
determining the therapeutic effect of the agent on the transgenic
non-human animal by monitoring basal synaptic transmission or
synaptic plasticity, wherein an increase in basal synaptic
transmission or synaptic plasticity indicates that the agent would
have a potential therapeutic effect on Alzheimer's disease in a
human.
8. The method of claim 7, wherein the promoter is platelet derived
growth factor (PDGF)-B-chain promoter.
9. The method of claim 7, wherein the non-human animal is a mouse,
a rat, a sheep, a dog, a primate, or a reptile.
10. The method of claim 7, wherein the non-human animal is a
mammal.
11. A method for identifying whether an agent or a compound is an
inhibitor of receptor for advanced glycation endproduct (RAGE) in
vivo, which comprises: (a) obtaining a non-human transgenic animal
whose cells overexpress RAGE in neurons; (b) administering an agent
or compound to the transgenic non-human animal; and (c) determining
whether the transgenic non-human animal from step (b) exhibits a
change in neuronal function from an identical transgenic non-human
animal which was not administered the agent or compound; wherein a
determination of change in neuronal function indicates that the
agent or compound is an inhibitor of RAGE in vivo.
Description
[0001] This application is a continuation of U.S. Ser. No.
12/908,832, filed Oct. 20, 2010, which is a continuation of U.S.
Ser. No. 09/638,653, filed Aug. 14, 2000, now U.S. Pat. No.
7,919,670, issued Apr. 5, 2011, the contents of which is hereby
incorporated by reference.
BACKGROUND OF THE INVENTION
[0002] Throughout this application, various publications are
referenced by number. Full citations for these publications may be
found listed at the end of the specification immediately preceding
the claims. The disclosures of these publications in their
entireties are hereby incorporated by reference into this
application in order to more fully describe the state of the art as
known to those skilled therein as of the date of the invention
described and claimed herein.
[0003] The pain of Alzheimer's disease results directly from the
memory loss and cognitive deficits suffered by the patient. These
eventually result in the patient's loss of identity, autonomy, and
freedom. As a step toward curing this disease, alleviating its
symptoms, or retarding its progression, it would be desirable to
develop a transgenic animal model exhibiting the main debilitating
phenotype of Alzheimer's disease, that is, memory loss, expressed
concomitantly with the neuropathological correlates of Alzheimer's
disease, for example, beta-amyloid accumulation, increased glial
reactivity, and hippocampal cell loss.
[0004] It is estimated that over 5% of the U.S. population over 65
and over 15% of the U.S. population over 85 are beset with some
form of Alzheimer's disease (Cross, A. J., Eur J Pharmacol (1982)
82:77-80: Terry, R. D., et al., Ann Neural (1983) 14:497506). It is
believed that the principal cause for confinement of the elderly in
long term care facilities is due to this disease, and approximately
65% of those dying in skilled nursing facilities suffer from
it.
[0005] Certain facts about the biochemical and metabolic phenomena
associated with the presence of Alzheimer's disease are known. Two
morphological and histopathological changes noted in Alzheimer's
disease brains are neurofibrillary tangles (NFT) and amyloid
deposits. Intraneuronal neurofibrillary tangles are present in
other degenerative diseases as well, but the presence of amyloid
deposits both in the interneuronal spaces (neuritic plaques) and in
the surrounding microvasculature (vascular plaques) seems to be
characteristic of Alzheimer's. Of these, the neuritic plaques seem
to be the most prevalent (Price, D. L., et al., Drug Development
Research (1985) 5:59-68). Plaques are also seen in the brains of
aged Down's Syndrome patients who develop Alzheimer's disease.
SUMMARY OF THE INVENTION
[0006] The present invention provides for a transgenic non-human
animal whose cells contain a DNA sequence comprising: (a) a nerve
tissue specific promoter; and (b) a DNA sequence which encodes a
receptor for advanced glycation endproducts (RAGE), wherein the
promoter and the DNA sequence which encodes the receptor for
advanced glycation endproducts (RAGE) are operatively linked to
each other and integrated in the genome of the non-human animal,
and wherein said non-human animal exhibits a reduced amount of
cerebral tissue infarcted following a transient middle cerebral
artery occlusion compared to an identical non-human animal lacking
said DNA sequence.
BRIEF DESCRIPTION OF THE FIGURES
[0007] FIGS. 1A-1B. Schematic depiction of strategy for making Tg
PD-RAGE mice.
[0008] FIG. 2. Southern analysis of three founders for Tg PD-RAGE
mice: lanes 1, 3, 6 show mice positive for the transgene and lanes
2, 4-5 are nontransgenic littermates.
[0009] FIG. 3. Identification of Tg PD-RAGE mice (+) and
nontransgenic littermate controls (-) by PCR.
[0010] FIGS. 4A-4B. RAGE expression in Tg PD-RAGE mice (+) compared
with nontransgenic littermate controls (-). A (Northern) and B
(Western) analysis of homogenates of cerebral cortex. Equal amounts
of RNA (note approximately equal intensity of 28S ribosomal RNA
band on the ethidium bromide stained gel) and protein were loaded
in each lane.
[0011] FIG. 5. RAGE expression in brain subregions of Tg PD-RAGE
mice compared with nontransgenic littermate controls (nonTg).
Immunoblotting was performed protein extracts of brain homogenates
derived from the indicated brain subregion.
[0012] FIG. 6A-6B Immunohistochemical identification of RAGE in
cerebral cortex from a Tg PD-RAGE mouse (FIG. 6A) and a
nontransgenic littermate control (FIG. 6B).
[0013] FIG. 7. Transient middle cerebral artery occlusion modal of
stroke in mice: comparison of infarct volume in Tg PD-RAGE and
nontransgenic littermate controls (nonTg). *P<0.05.
[0014] FIG. 8. Identification of double transgenic mice
overexpressing RAGE and mutant human APP by PCR.
[0015] FIGS. 9A, 9B1, 9B2, 9B3, 9C. Increased expression of M-CSF
in cerebral cortex from double Tg mice overexpressing RAGE and
mutant human APP (hAPP). FIG. 9A, Northern analysis for M-CSF
transcripts. FIGS. 9B1-9B3, immunostaining for M-CSF. FIG. 9C,
Quantitation of immunocytochemical results.
[0016] FIGS. 10A, 10B1, 10B2, 10B3, 10C. Increased expression of
Interleukin (IL)-6 in cerebral cortex from double Tg mice
overexpressing RAGE and mutant human APP (hAPP). FIG. 10A, Northern
analysis for IL-6 transcripts. FIGS. 10B1-10B3, immunostaining for
IL-6. FIG. 10C, Quantitation of immunocytochemical results.
[0017] FIG. 11. EMSA for NF-kB on nuclear extracts from cerebral
cortex of mice overexpressing RAGE (2,3), mutant human APP (hAPP;
4,5), both transgenes (6-9), and a nontransgenic littermate control
(1).
[0018] FIG. 12. Semiquantitative analysis of synaptophysin
immunoreactivity in hippocampus of Tg PD-RAGE/hAPP, Tg PD-RAGE, Tg
hAPP, and nontransgenic littermate control mice at 4 months of
age.
[0019] FIG. 13. Semiquantitative analysis of MAP-2 immunoreactivity
in hippocampus of Tg PD-RAGE/hAPP, Tg PD-RAGE, Tg hAPP, and
nontransgenic littermate control mice at 4 months of age. FIGS.
14A1, 14A2, 14A3, 14A4, and 14B. Increased expression of activated
caspase-3 in cerebral cortex from Tg PD-RAGE/hAPP mice. FIGS.
14A1-4, immunostaining for activated caspase-3. FIG. 14B,
quantitation of immunocytochemical results from multiple fields of
all mice in each of the experimental groups. Scale bar, 10
.mu.m.
[0020] FIGS. 15B1, 15A2, 15A3, 15A4, and 15B. Immunostaining (FIGS.
15A1-4) with antibody to phosphorylated tau (AT8) in cerebral
cortex of the indicated transgenic mice. FIG. 15B demonstrates
image analysis of multiple microscopic fields from all of the mice
in each of the experimental groups. Scale bar, 10 .mu.m.
[0021] FIG. 16. Immunoblotting of E16 cortical neuron cultures with
anti-human RAGE IgG. (+) indicates neurons obtained from Tg PD-RAGE
mice and (-) indicates neurons are from nontransgenic littermate
controls.
[0022] FIGS. 17A-17B. NF-kB activation in primary cortical neuron
cultures from Tg PD-RAGE and nontransgenic littermates exposed for
5 hrs to preformed A.beta.(1-40) fibrils (500 nM) alone (FIG. 17A
(left panel)) or in the presence of anti-RAGE IgG or nonimmune (NI)
IgG (FIG. 17B (right panel)). Gel shift analysis was performed with
.sup.32P-labelled NF-kB probe.
[0023] FIG. 18. Cortical neuron cultures (as in FIGS. 16-17) were
exposed to preformed A.beta.(1-40) fibrils (2 .mu.M) for 30 or 40
hours, and caspase-3 activity was monitored. Neurons were derived
from Tg PD.
[0024] FIGS. 19A-19B. Volume of infarcted cerebral tissue was
reduced in RAGE overexpressing transgenic mice compared with the
control mice. The volume was reduced about 50% (p<0.05) in the
transgenic mice compared with normal mice. FIG. 19A shows results
of studies in all mice; FIG. 19B shows triphenyl tetrazolium
chloride staining of selected cerebral sections.
DETAILED DESCRIPTION OF THE INVENTION
[0025] The present invention provides for a transgenic non-human
animal whose cells contain a DNA sequence comprising: (a) a nerve
tissue specific promoter; and (b) a DNA sequence which encodes a
receptor for advanced glycation endproducts (RAGE), wherein the
promoter and the DNA sequence which encodes the receptor for
advanced glycation endproducts (RAGE) are operatively linked to
each other and integrated in the genome of the non-human animal,
and wherein said non-human animal exhibits a reduced amount of
cerebral tissue infarcted following a transient middle cerebral
artery occlusion compared to an identical non-human animal lacking
said DNA sequence.
[0026] In one embodiment of the invention, the promoter is platelet
derived growth factor (PDGF)-B-chain promoter. In another
embodiment of the invention, the DNA sequence which encodes
amyloid-beta peptide alcohol dehydrogenase is a human DNA sequence.
In another embodiment, the reduction of infarcted cerebral tissue
is about a 50% reduction. In another embodiment, the transgenic
non-human animal is a mouse, a rat, a sheep, a dog, a primate, or a
reptile. In another embodiment of the invention, the non-human
animal is a mammal.
[0027] This invention also provides for a method for evaluating in
a non-human transgenic animal the potential therapeutic effect of
an agent for treating Alzheimer's disease in a human, which
comprises: (a) administering an agent to a transgenic non-human
animal whose cells comprise a nerve tissue specific promoter
operatively linked to a DNA sequence which encodes receptor for
advanced glycation endproducts (RAGE); and (b) determining the
therapeutic effect of the agent on the transgenic non-human animal
by monitoring basal synaptic transmission or synaptic plasticity,
wherein an increase in basal synaptic transmission or synaptic
plasticity indicates that the agent would have a potential
therapeutic effect on Alzheimer's disease in a human.
[0028] The invention also provides for a method for identifying
whether an agent or a compound is an inhibitor of receptor for
advanced glycation endproduct (RAGE) in vivo, which comprises (a)
obtaining a non-human transgenic animal whose cells overexpress
RAGE in neurons; (b) administering an agent or compound to the
transgenic non-human animal; (c) determining whether the transgenic
non-human animal from step (b) exhibits a change in neuronal
function from an identical transgenic non-human animal which was
not administered the agent or compound; wherein a determination of
change in neuronal function indicates that the agent or compound is
an inhibitor of RAGE in vivo.
[0029] In one embodiment of the invention, the promoter of both
element (a) and (b) is platelet derived growth factor
(PDGF)-B-chain promoter.
[0030] In another embodiment of the invention, the non-human animal
is a mouse, a rat, a sheep, a dog, a primate, or a reptile. In
another embodiment, the animal is a mammal.
[0031] The phenotype observed in the transgenic RAGE overexpressing
mice described herein was not obvious prior to the creation of such
mice. The transgenic mice described herein only overexpress RAGE in
neurons, whereas in the normal animal, RAGE is also expressed in
the microglia at high levels (the microglia are considered
important cells in the pathogenesis of Alzheimer's disease).
Therefore, prior to creating and studying the actual transgenic,
one could have imagined that overexpression of RAGE in neurons
alone would not have had a significant effect on the resulting
transgenic animal. However, as described hereinbelow, there is
evidence that RAGE overexpressing mice exhibit a reduced neurologic
deficit score and that RAGE overexpreseing mice have a reduced
volume of infarcted cerebral tissue when subjected to the transient
middle cerebral artery occlusion procedure (described below).
Nucleotide and Amino Acid Sequence of RAGE
[0032] The nucleotide and protein (amino acid) sequences for RAGE
(both human and murine and bovine) are known. The following
references which recite these sequences are incorporated by
reference: [0033] Schmidt et al, J. Biol. Chem., 267:14987-97, 1992
[0034] Neeper et al, J. Biol. Chem., 267:14998-15004, 1992
[0035] RAGE sequences (DNA sequence and translation) from bovine,
murine and homo sapien are listed hereinbelow. These sequences are
available from GenBank as are other sequences of RAGE from other
species:
TABLE-US-00001 LOCUS BOVRAGE 1426 by mRNA MAM 09 DEC. 1993
DEFINITION Cow receptor for advanced glycosylation end products
(RAGE) mRNA, complete cds. ACCESSION M91212VERSION M91212.1 GI:
163650 KEYWORDS RAGE; cell surface receptor. SOURCE Bos taurus cDNA
to mRNA. ORGANISM Bos taurus Eukaryota; Metazoa; Chordata;
Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria;
Cetartiodactyla; Ruminantia; Pecora; Bovoidea; Bovidae; Bovinae;
Bos. REFERENCE 1 (bases 1 to 1426) AUTHORS Neeper, M., Schmidt, A.
M., Brett, J., Yan, S. D., Wang, F., Pan, Y. C., Elliston, K.,
Stern, D. and Shaw, A. TITLE Cloning and expression of a cell
surface receptor for advanced glycosylation end products of
proteins JOURNAL J. Biol. Chem. 267, 14998-15004 (1992) MEDLINE
92340547 REFERENCE 2 (bases 1 to 1426) AUTHORS Shaw, A. TITLE
Direct Submission JOURNAL Submitted (15 APR. 1992) A. Shaw,
Department of Cellular and Molecular Biology, Merck Sharp and Dohme
Research Laboratories, West Point, PA 19486 USAFEATURES
Location/Qualifiers source 1 . . . 1426 /organism = "Bos taurus"
/db_xref = "taxon: 9913" /tissue_type = "lung" CDS 10 . . . 1260
/standard_name = "RAGE" /codon_start = 1 /product = "receptor for
advanced glycosylation end products" /protein_id = "AAA03575.1"
/db_xref = "GI: 163651" /translation='' (SEQ ID NO: 1) M A A G A V
V G A W M L V L S L G G T V T G D Q N I T A R I G K P L V L N C K G
A P K K PPQQLEWKLNTGRTEAWKVLSPQGDPWDSVARVLPNGSLLLPAVGIQDEGTFRCRATS
RSGKETKSNYRVRVYQIPGKPEIVDPASELMAGVPNKVGTCVSEGGYPAGTLNWLLDG
KTLIPDGEGVSVKEETERHPKTGLFTLHSELMVTPARGGALHPTFSCSFTPGLPRRRA
LHTAPIQLRVWSEHRGGEGPNVDAVPLKEVQLVVEPEGGAVAPGGTVTLTCEAPAQPP
PQIHWIKDGRPLPLPPGPMLLLPEVGPEDQGTYSCVATHPSHGPQESRAVSVTIIETG
EEGTTAGSVEGPGLETLALTLGILGGLGTVALLIGVIVWHRRRQRKGQERKVPENQEE
EEEERAELNQPEEPEAAESSTGGP polyA_signal 1406 . . . 1411 polyA_site
1426 BASE COUNT 322 a 429 c 440 g 235 t ORIGIN (SEQ ID NO: 2) 1
cggagaagga tggcagcagg ggcagtggtc ggagcctgga tgctagtcct cagtctgggg
61 gggacagtca cgggggacca aaacatcaca gcccggatcg ggaagccact
ggtgctgaac 121 tgcaagggag cccccaagaa accaccccag cagctggaat
ggaaactgaa cacaggccgg 181 acagaagctt ggaaagtcct gtctccccag
ggagacccct gggatagcgt ggctcgggtc 241 ctccccaacg gctccctcct
cctgccggct gttgggatcc aggatgaggg gactttccgg 301 tgccgggcaa
cgagccggag cggaaaggag accaagtcca actaccgagt ccgagtctat 361
cagattcctg ggaagccaga aattgttgac cctgcctctg aactcatggc tggtgtcccc
421 aataaggtgg ggacatgtgt gtccgagggg ggctaccctg cagggactct
taactggctc 481 ttggatggga aaactctgat tcctgatggc aaaggagtgt
cagtgaagga agagaccaag 541 agacacccaa agacagggct tttcacgctc
cattcggagc tgatggtgac cccagctcgg 601 ggaggagctc tccaccccac
cttctcctgt agcttcaccc ctggccttcc ccggcgccga 661 gccctgcaca
cggcccccat ccagctcagg gtctggagtg agcaccgagg tggggagggc 721
cccaacgtgg acgctgtgcc actgaaggaa gtccagttgg tggtagagcc agaaggggga
781 gcagtagctc ctggtggtac tgtgaccttg acctgtgaag cccccgccca
gcccccacct 841 caaatccact ggatcaagga tggcaggccc ctgccccttc
cccctggccc catgctgctc 901 ctcccagagg tagggcctga ggaccaggga
acctacagtt gtgtggccac ccatcccagc 961 catgggcccc aggagagccg
tgctgtcagc gtcacgatca tcgaaacagg cgaggagggg 1021 acgactgcag
gctctgtgga agggccgggg ctggaaaccc tagccctgac cctggggatc 1081
ctgggaggcc tggggacagt cgccctgctc attggggtca tcgtgtggca tcgaaggcgg
1141 caacgcaaag gacaggagag gaaggtcccg gaaaaccagg aggaggaaga
ggaggagaga 1201 gcggaactga accagccaga ggagcccgag gcggcagaga
gcagcacagg agggccttga 1261 ggagcccacg gccagacccg atccatcagc
cccttttctt ttcccacact ctgttctggc 1321 cccagaccag ttctcctctg
tataatctcc agcccacatc tcccaaactt tcttccacaa 1381 ccagagcctc
ccacaaaaag tgatgagtaa acacctgcca cattta//
TABLE-US-00002 LOCUS HUMRAGE 1391 bp mRNA PRI 09 DEC. 1993
DEFINITION Human receptor for advanced glycosylation end products
(RAGE) mRNA, partial cds. ACCESSION M91211VERSION M91211.1 GI:
190845 KEYWORDS RAGE; cell surface receptor. SOURCE Homo sapiens
cDNA to mRNA. ORGANISM Homo sapiens Eukaryota; Metazoa; Chordata;
Craniata; Vertebrate; Euteleostomi; Mammalia; Eutheria; Primates;
Catarrhini; Hominidae; Homo. REFERENCE 1 (bases 1 to 1391) AUTHORS
Neeper, M., Schmidt, A. M., Brett, J., Yan, S. D., Wang, F., Pan,
Y. C., Elliston, K., Stern, D. and Shaw, A. TITLE Cloning and
expression of a cell surface receptor for advanced glycosylation
end products of proteins JOURNAL J. Biol. Chem. 267, 14998-15004
(1992) MEDLINE 92340547 REFERENCE 2 (bases 1 to 1391) AUTHORS Shaw,
A. TITLE Direct Submission JOURNAL Submitted (15 APR, 1992) A.
Shaw, Department of Cellular and Molecular Biology, Merck Sharp and
Dohme Research Laboratories, West Point, PA 19486 USA FEATURES
Location/Qualifiers source 1 . . . 1391 /organism = "Homo sapiens"
/db_xref = "taxon: 9606" /tissue_type = "lung" CDS < 1 . . .
1215 /standard_name = "RAGE" /codon_start = 1 /product = "receptor
for advanced glycosylation end products" /protein_id = "AAA03574.1"
/db_xref = "GI: 190846" /translation'' (SEQ ID NO: 3) G A A G T A V
G A W V L V L S L W G A V V G A Q N I T A R I G E P L V L K C K G A
P K K PPQRLEWKLNTGRTEAWKVLSPQGGGPWDSVARVLPNGSLFLPAVGIQDEGIFRCRAM
NRNGKETKSNYRVRVYQIPGKPEIVDSASELTAGVPNKVGTCVSEGSYPAGTLSWHLD
GKPLVPNEKGVSVKEQTRRHPETGLFTLQSELMVTPARGGDPRPTFSCSFSPGLPRHR
ALRTAPIQPRVWEPVPLEEVQLVVEPEGGAVAPGGTVTLTCEVPAQPSPQIHWMKDGV
PLPLPPSPVLILPEIGPQDQGTYSCVATHSSHGPQESRAVSISIIEPGEEGPTAGSVG
GSGLGTLALALGILGGLGTAALLIGVILWQRRQRRGEERKAPENQEEEEERAELNQSE
EPEAGESSTGGP polyA_signal 1368 . . . 1373 polyA_site 1391 BASE
COUNT 305 a 407 c 418 g 261 t ORIGIN (SEQ ID NO: 4) 1 ggggcagccg
gaacagcagt tggagcctgg gtgctggtcc tcagtctgtg gggggcagta 61
gtaggtgctc aaaacatcac agcccggatt ggcgagccac tggtgctgaa gtgtaagggg
121 gcccccaaga aaccacccca gcggctggaa tggaaactga acacaggccg
gacagaagct 181 tggaaggtcc tgtctcccca gggaggaggc ccctgggaca
gtgtggctcg tgtccttccc 241 aacggctccc tcttccttcc ggctgtcggg
atccaggatg aggggatttt ccggtgcagg 301 gcaatgaaca ggaatggaaa
ggagaccaag tccaactacc gagtccgtgt ctaccagatt 361 cctgggaagc
cagaaattgt agattctgcc tctgaactca cggctggtgt tcccaataag 421
gtggggacat gtgtgtcaga gggaagctac cctgcaggga ctcttagctg gcacttggat
481 gggaagcccc tggtgcctaa tgagaaggga gtatctgtga aggaacagac
caggagacac 541 cctgagacag ggctcttcac actgcagtcg gagctaatgg
tgaccccagc ccggggagga 601 gatccccgtc ccaccttctc ctgtagcttc
agcccaggcc ttccccgaca ccgggccttg 661 cgcacagccc ccatccagcc
ccgtgtctgg gagcctgtgc ctctggagga ggtccaatcg 721 gtggtggagc
cagaaggtgg agcagtagct cctggtggaa ccgtaaccct gacctgtgaa 781
gtccctgccc agccctctcc tcaaatccac tggatgaagg atggtgtgcc cttgcccctt
841 ccccccagcc ctgtgctgat cctccctgag atagggcctc aggaccaggg
aacctacagc 901 tgtgtggcca cccattccag ccacgggccc caggaaagcc
gtgctgtcag catcagcatc 961 atcgaaccag gcgaggaggg gccaactgca
ggctctgtgg gaggatcagg gctgggaact 1021 ctagccctgg ccctggggat
cctgggaggc ctggggacag ccgccctgct cattggggtc 1081 atcctgtggc
aaaggcggca acgccgagga gaggagagga aggccccaga aaaccaggag 1141
gaagaggagg agcgtgcaga actgaatcag tcggaggaac ctgaggcagg cgagagtagt
1201 actggagggc cttgaggggc ccacagacag atcccatcca tcagctccct
tttcttttcc 1261 ccttgaactg ttctggcctc agaccaactc tctcctgtat
aatctctctc ctgtataacc 1321 ccaccttgcc aagctttctt ctacaaccag
agccccccac aatgatgatt aaacacctga 1381 cacatcttgc a//
TABLE-US-00003 LOCUS MUSRECEP 1348 bp mRNA ROD 23 AUG. 1994
DEFINITION Mouse receptor for advanced glycosylation end products
(RAGE) gene, complete cds. ACCESSION L33412VERSION L334I2.1 GI:
532208 KEYWORDS receptor for advanced glycosylation end products.
SOURCE Mus musculus (strain BALB/c, sub_species domesticus)
(library: lambda gt10) male adult lung cDNA to mRNA. ORGANISM Mus
musculus Eukaryota; Metazoa; Chordata; Craniata; Vertebrata;
Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae;
Murine; Mus. REFERENCE 1 (bases 1 to 1348) AUTHORS Lundh, E. R.,
Morser, J., McClary, J. and Nagashima, M. TITLE Isolation and
characterization of cDNA encoding the murine and rat homologues of
the mammalian receptor for advanced glycosylation end products
JOURNAL UnpublishedCOMMENT On Aug. 24, 1994 this sequence version
replaced gi: 496I46. FEATURES Location/Qualifiers source 1 . . .
1348 /organism = "Mus musculus" /strain = "BALB/c" /sub_species =
"domesticus" /db_xref = "taxon: 10090" /sex = "male" /tissue_type =
"1ung" /dev_stage = "adult" /tissue_lib = "lambda gt10" gene 6 . .
. 1217 /gene = "RAGE" CDS 6 . . . 1217 /gene = "RAGE" /codon_start
= 1 /product = "receptor for advanced glycosylation end products"
/protein_id = "AAA40040.1" /db_xref = "GI: 532209" /translation=''
(SEQ ID NO: 5) M P A G T A A R A W V L V L A L W G A V A G G Q N I
T A R I G E P L V L S C K G A P K K
PPQQLEWKLNTGRTEAWKVLSPQGGPWDSVAQILPNGSLLLPATGIVDEGTFRCRATN
RRGKEVKSNYRVRVYQIPGKPEIVDPASELTASVPNKVGTCVSEGSYPAGTLSWHLDG
KLLIPDGKETLVKEETRRHPETGLFTLRSELTVIPTQGGTTHPTFSCSFSLGLPRRRP
LNTAPIQLRVREPGPPEGIQLLVEPEGGIVAPGGTVTLTCAISAQPPPQVHWIKDGAP
LPLAPSPVLLLPEVGHADEGTYSCVATHPSHGPQESPPVSIRVTETGDEGPAEGSVGE
SGLGTLALALGILGGLGVVALLVGAILWRKRQPRREERKAPESQEDEEERAELNQSEE
AEMPENGAGGP polyA_site 1333 BASE COUNT 301 a 394 c 404 g 249 t
ORIGIN (SEQ ID NO: 6) 11 gcaccatgcc agcggggaca gcagctagag
cctgggtgct ggttcttgct ctatggggag 61 ctgtagctgg tggtcagaac
atcacagccc ggattggaga gccacttgtg ctaagctgta 121 agggggcccc
taagaagccg ccccagcagc tagaatggaa actgaacaca ggaagaactg 181
aagcttggaa ggtcctctct ccccagggag gcccctggga cagcgtggct caaatcctcc
241 ccaatggttc cctcctcctt ccagccactg gaattgtcga tgaggggacg
ttccggtgtc 301 gggcaactaa caggcgaggg aaggaggtca agtccaacta
ccgagtccga gtctaccaga 361 ttcctgggaa gccagaaatt gtggatcctg
cctctgaact cacagccagt gtccctaata 421 aggtggggac atgtgtgtct
gagggaagct accctgcagg gacccttagc tggcacttag 481 atgggaaact
tctgattccc gatggcaaag aaacactcgt gaaggaagag accaggagac 541
accctgagac gggactcttt acactgcggt cagagctgac agtgatcccc acccaaggag
601 gaaccaccca tcctaccttc tcctgcagtt tcagcctggg ccttccccgg
cgcagacccc 661 tgaacacagc ccctatccaa ctccgagtca gggagcctgg
gcctccagag ggcattcagc 721 tgttggttga gcctgaaggt ggaatagtcg
ctcctggtgg gactgtgacc ttgacctgtg 781 ccatctctgc ccagccccct
cctcaggtcc actggataaa ggatggtgca cccttgcccc 841 tggctcccag
ccctgtgctg ctcctccctg aggtggggca cgcggatgag ggcacctata 901
gctgcgtggc cacccaccct agccacggac ctcaggaaag ccctcctgtc agcatcaggg
961 tcacagaaac cggcgatgag gggccagctg aaggctctgt gggtgagtct
gggctgggta 1021 cgctagccct ggccttgggg atcctgggag gcctgggagt
agtagccctg ctcgtcgggg 1081 ctatcctgtg gcgaaaacga caacccaggc
gtgaggagag gaaggccccg gaaagccagg 1141 aggatgagga ggaacgtgca
gagctgaatc agtcagagga agcggagatg ccagagaatg 1201 gtgccggggg
accgtaagag cacccagatc gagcctgtgt gatggcccta gagcagctcc 1261
cccacattcc atcccaattc ctccttgagg cacttccttc tccaaccaga gcccacatga
1321 tccatgctga gtaaacattt gatacggc//
DEFINITIONS
[0036] "DNA sequence" is a linear sequence comprised of any
combination of the four DNA monomers, i.e., nucleotides of adenine,
guanine, cytosine and thymine, which codes for genetic information,
such as a code for an amino acid, a promoter, a control or a gene
product. A specific DNA sequence is one which has a known specific
function, e.g., codes for a particular polypeptide, a particular
genetic trait or affects the expression of a particular
phenotype.
[0037] "Genotype" is the genetic constitution of an organism.
[0038] "Phenotype" is a collection of morphological, physiological
and biochemical traits possessed by a cell or organism that results
from the interaction of the genotype and the environment.
[0039] "Phenotypic expression" is the expression of the code of a
DNA sequence or sequences which results in the production of a
product, e.g., a polypeptide or protein, or alters the expression
of the zygote's or the organisms natural phenotype.
[0040] "Zygote" is a diploid cell having the potential for
development into a complete organism. The zygote can result from
parthenogenesis, nuclear transplantation, the merger of two gametes
by artificial or natural fertilization or any other method which
creates a diploid cell having the potential for development into a
complete organism. The origin of the zygote can be from either the
plant or animal kingdom.
[0041] In the practice of any of the methods of the invention or
preparation of any of the pharmaceutical compositions an
"therapeutically effective amount" is an amount which is capable of
alleviating the symptoms of the cognitive disorder of memory or
learning in the subject. Accordingly, the effective amount will
vary with the subject being treated, as well as the condition to be
treated. For the purposes of this invention, the methods of
administration are to include, but are not limited to,
administration cutaneously, subcutaneously, intravenously,
parenterally, orally, topically, or by aerosol.
[0042] By "nervous system-specific" is meant that expression of a
nucleic acid sequence occurs substantially in a nervous system
tissue (for example, the brain or spinal cord). Preferably, the
expression of the nucleic acid sequence in the nervous system
tissue represents at least a 5-fold, more preferably, a 10-fold,
and, most preferably, a 100-fold increase over expression in
non-nervous system tissue.
[0043] The "non-human animals" of the invention include vertebrates
such as rodents, non-human primates, sheep, dog, cow, amphibians,
reptiles, etc. Preferred non-human animals are selected from the
rodent family including rat and mouse, most preferably mouse.
[0044] The "transgenic non-human animals" of the invention are
produced by introducing "transgenes" into the germline of the
non-human animal.
ADVANTAGES OF THE PRESENT INVENTION
[0045] The transgenic non-human mammals of the present invention
will provide insights with respect to how and where protein
interactions occur in Alzheimer's Disease and thus provide more
useful models for testing the efficacy of certain drugs in
preventing or reducing the onset or progression of this disease.
The transgenic non-human mammals of the present invention include
recombinant genetic material comprised of a nucleic acid sequence
encoding RAGE fused to specific promoters capable of expressing the
protein in specific tissues such as nerve tissues generally and/or
specific types of nerve tissue, e.g., the brain.
[0046] As described herein, the current invention provides a number
of advantages. First, because transgenic animals are generally
useful for the investigation of specific biological processes and
for reproducing particular aspects of human disease, the transgenic
animals of the invention provide an important, reproducible and
accurate means for screening drugs to isolate therapeutic agents.
In particular, the transgenic animals that are described for the
first time herein have the advantage of mimicking the defects
observed in patients with Alzheimer's disease. Accordingly, the
efficacy of a particular therapy may be examined in the same animal
at different disease stages. Importantly, because this invention
provides a transgenic animal model of Alzheimer's disease with
measurable phenotypes, compounds may be screened to identify those
which alleviate this symptom, even absent knowledge of the
symptom's underlying biological cause.
[0047] In addition, although not strictly required for drug
screening, the associated neuro-pathological symptoms exhibited by
the transgenic animal models described herein provide the unique
advantage of allowing the investigation of the etiology of
Alzheimer's disease. For example, the appearance of reduced
synaptic plasticity or the reduced basal synaptic transmission may
be correlated with the appearance of specific behavioral
impairments within individuals or groups of animals. In addition,
treatments which are shown to improve memory function may be tested
for their ability to selectively improve certain pathological
symptoms.
[0048] Another advantage of this invention is the ease with which
these transgenic animals are bred to produce identical transgenic
progeny. The animals of the invention may be generated in
sufficient quantity to make them widely and rapidly available to
researchers in this field.
FURTHER DETAILED DESCRIPTION OF THE INVENTION
[0049] The present invention also provides for a transgenic
nonhuman animal whose germ or somatic cells contain a nucleic acid
molecule which comprises: (a) a neuronal tissue specific promoter
operatively linked to a DNA sequence encoding a receptor for
advanced glycation endproduct (RAGE), introduced into the mammal,
or an ancestor thereof, at an embryonic stage.
[0050] This transgenic animal may be used in screening methods for
compounds which would be useful in the treatment of neurological
disorders in humane. A method for screening compounds for their
potential use as therapeutic agents which comprises administering
to the transgenic non-human mammal described herein the compound,
in various amounts, and observing whether the neurological function
of the transgenic mammal improves or not (as determined by, for
example, basal synaptic transmission, synaptic plasticity, neuronal
stress, et al.).
[0051] The neurological disorder may be amnesia, Alzheimer's
disease, amyotrophic lateral sclerosis, a brain injury, cerebral
senility, chronic peripheral neuropathy, a cognitive disability, a
degenerative disorder associated with learning, Down's Syndrome,
dyslexia, electric shock induced amnesia or amnesia. Guillain-Barre
syndrome, head trauma, Huntington's disease, a learning disability,
a memory deficiency, memory loss, a mental illness, mental
retardation, memory or cognitive dysfunction, multi-infarct
dementia and senile dementia, myasthenia gravis, a neuromuscular
disorder, Parkinson's disease, Pick's disease, a reduction in
spatial memory retention, senility, or Turret's syndrome.
[0052] The compound which is tested in the screening method of the
present invention may be an organic compound, a nucleic acid, a
small molecule, an inorganic compound, a lipid, or a synthetic
compound. The mammal may be a mouse, a sheep, a bovine, a canine, a
porcine, or a primate. The administration may comprise
intralesional, intraperitoneal, intramuscular or intravenous
injection; infusion; liposome-mediated delivery; gene bombardment;
topical, nasal, oral, anal, ocular or otic delivery.
[0053] The present invention also provides for a method for
alleviating symptoms in a subject suffering from a neurological
disorder which comprises administering to the subject an effective
amount of the compound evaluated by the methods hereinabove in an
amount effective to treat the symptoms in the subject suffering
from a neurological disorder.
[0054] The administration may be intralesional, intraperitoneal,
intramuscular or intravenous injection; infusion; liposome-mediated
delivery; gene bombardment; topical, nasal, oral, anal, ocular or
otic delivery.
Pharmaceutical Compositions and Carriers
[0055] As used herein, the term "suitable pharmaceutically
acceptable carrier" encompasses any of the standard
pharmaceutically accepted carriers, such as phosphate buffered
saline solution, water, emulsions such as an oil/water emulsion or
a triglyceride emulsion, various types of wetting agents, tablets,
coated tablets and capsules. An example of an acceptable
triglyceride emulsion useful in intravenous and intraperitoneal
administration of the compounds is the triglyceride emulsion
commercially known as Intralipid.RTM..
[0056] Typically such carriers contain excipients such as starch,
milk, sugar, certain types of clay, gelatin, stearic acid, talc,
vegetable fats or oils, gums, glycols, or other known excipients.
Such carriers may also include flavor and color additives or other
ingredients.
[0057] This invention also provides for pharmaceutical compositions
including therapeutically effective amounts of protein compositions
and compounds together with suitable diluents, preservatives,
solubilizers, emulsifiers, adjuvants and/or carriers useful in
treatment of neuronal degradation due to aging, a learning
disability, or a neurological disorder. Such compositions are
liquids or lyophilized or otherwise dried formulations and include
diluents of various buffer content (e.g., Tris-HCl, acetate,
phosphate), pH and ionic strength, additives such as albumin or
gelatin to prevent absorption to surfaces, detergents (e.g., Tween
20, Tween 80, Pluronic F68, bile acid salts), solubilizing agents
(e.g., glycerol, polyethylene glycerol), anti-oxidants (e.g.,
ascorbic acid, sodium metabisulfite), preservatives (e.g.,
Thimerosal, benzyl alcohol, parabens), bulking substances or
tonicity modifiers (e.g., lactose, mannitol), covalent attachment
of polymers such as polyethylene glycol to the compound,
complexation with metal ions, or incorporation of the compound into
or onto particulate preparations of polymeric compounds such as
polylactic acid, polyglycolic acid, hydrogels, etc, or onto
liposomes, micro emulsions, micelles, unilamellar or multi lamellar
vesicles, erythrocyte ghosts, or spheroplasts. Such compositions
will influence the physical state, solubility, stability, rate of
in vivo release, and rate of in vivo clearance of the compound or
composition. The choice of compositions will depend on the physical
and chemical properties of the compound.
[0058] Controlled or sustained release compositions include
formulation in lipophilic depots (e.g., fatty acids, waxes, oils).
Also comprehended by the invention are particulate compositions
coated with polymers (e.g., poloxamers or poloxamines) and the
compound coupled to antibodies directed against tissue-specific
receptors, ligands or antigens or coupled to ligands of
tissue-specific receptors. Other embodiments of the compositions of
the invention incorporate particulate forms protective coatings,
protease inhibitors or permeation enhancers for various routes of
administration, including parenteral, pulmonary, nasal and
oral.
[0059] Portions of the compound of the invention may be "labeled"
by association with a detectable marker substance (e.g.,
radiolabeled with .sup.125I or biotinylated) to provide reagents
useful in detection and quantification of compound or its receptor
bearing cells or its derivatives in solid tissue and fluid samples
such as blood, cerebral spinal fluid or urine.
[0060] When administered, compounds are often cleared rapidly from
the circulation and may therefore elicit relatively short-lived
pharmacological activity. Consequently, frequent injections of
relatively large doses of bioactive compounds may by required to
sustain therapeutic efficacy. Compounds modified by the covalent
attachment of water-soluble polymers such as polyethylene glycol,
copolymers of polyethylene glycol and polypropylene glycol,
carboxymethyl cellulose, dextran, polyvinyl alcohol,
polyvinylpyrrolidone or polyproline are known to exhibit
substantially longer half-lives in blood following intravenous
injection than do the corresponding unmodified compounds
(Abuchoweki et al., 1981; Newmark et al., 1982; and Katre et al.,
1987). Such modifications may also increase the compound's
solubility in aqueous solution, eliminate aggregation, enhance the
physical and chemical stability of the compound, and greatly reduce
the immunogenicity and reactivity of the compound. As a result, the
desired in vivo biological activity may be achieved by the
administration of such polymer-compound adducts less frequently or
in lower doses than with the unmodified compound.
[0061] Attachment of polyethylene glycol (PEG) to compounds is
particularly useful because PEG has very low toxicity in mammals
(Carpenter et al., 1971). For example, a PEG adduct of adenosine
deaminase was approved in the United States for use in humans for
the treatment of severe combined immunodeficiency syndrome. A
second advantage afforded by the conjugation of PEG is that of
effectively reducing the immunogenicity and antigenicity of
heterologous compounds. For example, a PEG adduct of a human
protein might be useful for the treatment of disease in other
mammalian species without the risk of triggering a severe immune
response. The compound of the present invention capable of
alleviating symptoms of a cognitive disorder of memory or learning
may be delivered in a microencapsulation device so as to reduce or
prevent an host immune response against the compound or against
cells which may produce the compound. The compound of the present
invention may also be delivered microencapsulated in a membrane,
such as a liposome.
[0062] Polymers such as PEG may be conveniently attached to one or
more reactive amino acid residues in a protein such as the
alpha-amino group of the amino terminal amino acid, the epsilon
amino groups of lysine side chains, the sulfhydryl groups of
cysteine side chains, the carboxyl groups of aspartyl and glutamyl
side chains, the alpha-carboxyl group of the carboxy-terminal amino
acid, tyrosine side chains, or to activated derivatives of glycosyl
chains attached to certain asparagine, serine or threonine
residues.
[0063] Numerous activated form a of PEG suitable for direct
reaction with proteins have been described. Useful PEG reagents for
reaction with protein amino groups include active esters of
carboxylic acid or carbonate derivatives, particularly those in
which the leaving groups are N-hydroxysuccinimide, p-nitrophenol,
imidazole or 1-hydroxy-2-nitrobenzene-4-sulfonate. PEG derivatives
containing maleimido or haloacetyl groups are useful reagents for
the modification of protein free sulfhydryl groups. Likewise, PEG
reagents containing amino hydrazine or hydrazide groups are useful
for reaction with aldehydes generated by periodate oxidation of
carbohydrate groups in proteins.
[0064] In one embodiment the compound of the present invention is
associated with a pharmaceutical carrier which includes a
pharmaceutical composition. The pharmaceutical carrier may be a
liquid and the pharmaceutical composition would be in the form of a
solution. In another embodiment, the pharmaceutically acceptable
carrier is a solid and the composition is in the form of a powder
or tablet. In a further embodiment, the pharmaceutical carrier is a
gel and the composition is in the form of a suppository or cream.
In a further embodiment the active ingredient may be formulated as
a part of a pharmaceutically acceptable transdermal patch.
Transgenic Technology and Materials
[0065] The following U.S. patents are hereby incorporated by
reference: U.S. Pat. No. 6,025,539, IL-5 transgenic mouse; U.S.
Pat. No. 6,023,010, Transgenic non-human animals depleted in a
mature lymphocytic cell-type; U.S. Pat. No. 6,018,098, In vivo and
in vitro model of cutaneous photoaging; U.S. Pat. No. 6,018,097,
Transgenic mice expressing human insulin; U.S. Pat. No. 6,008,434,
Growth differentiation factor-11 transgenic mice; U.S. Pat. No.
6,002,066; H2-M modified transgenic mice; U.S. Pat. No. 5,994,618,
Growth differentiation factor-8 transgenic mice; U.S. Pat. No.
5,986,171, Method for examining neurovirulence of polio virus, U.S.
Pat. No. 5,981,830, Knockout mice and their progeny with a
disrupted hepsin gene; U.S. Pat. No. 5,981,829, .DELTA.Nur77
transgenic mouse; U.S. Pat. No. 5,936,138; Gene encoding mutant
L3T4 protein which facilitates HIV infection and transgenic mouse
expressing such protein; U.S. Pat. No. 5,912,411, Mice transgenic
for a tetracycline-inducible transcriptional activator; U.S. Pat.
No. 5,894,078, Transgenic mouse expressing C-100 app.
[0066] The methods used for generating transgenic mice are well
known to one of skill in the art. For example, one may use the
manual entitled "Manipulating the Mouse Embryo" by Brigid Hogan at
al. (Ed. Cold Spring Harbor Laboratory) 1986.
[0067] See for example, Leder and Stewart, U.S. Pat. No. 4,736,866
for methods for the production of a transgenic mouse.
[0068] For sometime it has been known that it is possible to carry
out the genetic transformation of a zygote (and the embryo and
mature organism which result therefrom) by the placing or insertion
of exogenous genetic material into the nucleus of the zygote or to
any nucleic genetic material which ultimately forms a part of the
nucleus of the zygote. The genotype of the zygote and the organism
which results from a zygote will include the genotype of the
exogenous genetic material. Additionally, the inclusion of
exogenous genetic material in the zygote will result in a phenotype
expression of the exogenous genetic material.
[0069] The genotype of the exogenous genetic material is expressed
upon the cellular division of the zygote. However, the phenotype
expression, e.g., the production of a protein product or products
of the exogenous genetic material, or alterations of the zygote's
or organism's natural phenotype, will occur at that point of the
zygote's or organism's development during which the particular
exogenous genetic material is active. Alterations of the expression
of the phenotype include an enhancement or diminution in the
expression of a phenotype or an alteration in the promotion and/or
control of a phenotype, including the addition of a new promoter
and/or controller or supplementation of an existing promoter and/or
controller of the phenotype.
[0070] The genetic transformation of various types of organisms in
disclosed and described in detail in U.S. Pat. No. 4,873,191,
issued Oct. 10, 1989, which is incorporated herein by reference to
disclose methods of producing transgenic organisms. The genetic
transformation of organisms can be used as an in viva analysis of
gene expression during differentiation and in the elimination or
diminution of genetic diseases by either gene therapy or by using a
transgenic non-human mammal as a model system of a human disease.
This model system can be used to test putative drugs for their
potential therapeutic value in humans.
[0071] The exogenous genetic material can be placed in the nucleus
of a mature egg. It is preferred that the egg be in a fertilized or
activated (by parthenogenesis) state. After the addition of the
exogenous genetic material, a complementary haploid set of
chromosomes (e.g., a sperm cell or polar body) is added to enable
the formation of a zygote. The zygote is allowed to develop into an
organism such as by implanting it in a pseudopregnant female. The
resulting organism is analyzed for the integration of the exogenous
genetic material. If positive integration is determined, the
organism can be used for the in vivo analysis of the gene
expression, which expression is believed to be related to a
particular genetic disease.
[0072] Attempts have been made to study a number of different types
of genetic diseases utilizing such transgenic animals. Attempts
related to studying Alzheimer's disease are disclosed within
published PCT application WO89/06689 and PCT application
WO89/06693, both published on Jul. 27, 1989, which published
applications are incorporated herein by reference to disclose
genetic sequences coding for Alzheimer's .beta.-amyloid protein and
the incorporation of such sequences into the genome of transgenic
animals.
[0073] Embryonal target cells at various developmental stages can
be used to introduce transgenes. Different methods are used
depending on the stage of development of the embryonal target cell.
The zygote is the best target for micro-injection. In the mouse,
the male pronucleus reaches the size of approximately 20
micrometers in diameter which allows reproducible injection of 1-2
.mu.l of DNA solution. The use of zygotes as a target for gene
transfer has a major advantage in that in most cases the injected
DNA will be incorporated into the host gene before the first
cleavage (Hrinster, et al. (1985) Proc. Natl. Acad. Sci. U.S.A. 82,
4438-4442). As a consequence, all cells of the transgenic non-human
animal carry the incorporated transgene. This will in general also
be reflected in the efficient transmission of the transgene to
offspring of the founder since 50% of the germ cells will harbor
the transgene. Microinjection of zygotes is the preferred method
for incorporating transgenes in practicing the invention.
[0074] Retroviral infection can also be used to introduce transgene
into a non-human animal. The developing non-human embryo can be
cultured in vitro to the blastocyst stage. During this time, the
blastomeres can be targets for retroviral infection (Jaenich, R.
(1976) Proc. Natl. Acad. Sci. U.S.A. 73, 1260-1264). Efficient
infection of the blastomeres is obtained by enzymatic treatment to
remove the zona pellucida (Hogan, et al. (1986) in Manipulating the
Mouse Embryo, Cold Spring Harbor Laboratory Press, Cold Spring
Harbor, N.Y.). The viral vector system used to introduce the
transgene is typically a replication-defective retrovirus carrying
the transgene (Jahner, et al. (1985) Proc. Natl. Acad. Sci. U.S.A.
82, 6927-6931; Van der Putten, at al. (1985) Proc. Natl. Acad. Sci.
U.S.A. 82, 6148-6152). Transfection is easily and efficiently
obtained by culturing the blastomeres on a monolayer of
virus-producing cells (Van der Putten, supra; Stewart, et al.
(1987) EMBO J. 6, 383-388). Alternatively, infection can be
performed at a later stage. Virus or virus-producing cells can be
injected into the blastocoele (Jahner, D., et al. (1982) Nature
298, 623-628). Most of the founders will be mosaic for the
transgene since incorporation occurs only in a subset of the cells
which formed the transgenic non-human animal. Further, the founder
may contain various retroviral insertions of the transgene at
different positions in the genome which generally will segregate in
the offspring. In addition, it is also possible to introduce
transgenes into the germ line, albeit with low efficiency, by
intrauterine retroviral infection of the midgestation embryo
(Jahner, D. et al. (1982) supra).
[0075] A third type of target cell for transgene introduction is
the embryonal stem cell (ES). ES cells are obtained from
pre-implantation embryos cultured in vitro and fused with embryos
(Evans, M. J., et al. (1981) Nature 292, 154-156; Bradley, M. O.,
at al. (1984) Nature 309, 255-258; Gossler, et al. (1986) Proc.
Natl. Acad. Sci. U.S.A. 83, 9065-9069; and Robertson, at al. (1986)
Nature 322, 445-448). Transgenes can be efficiently introduced into
the ES cells by DNA transfection or by retrovirus-mediated
transduction. Such transformed ES cells can thereafter be combined
with blastocysts from a non-human animal. The ES cells thereafter
colonize the embryo and contribute to the germ line of the
resulting chimeric animal. For review see Jaenisch, R. (1988)
Science 240, 1468-1474.
[0076] As used herein, a "transgene" is a DNA sequence introduced
into the germline of a non-human animal by way of human
intervention such as by way of the above described methods.
[0077] The disclosures of publications referenced in this
application in their entireties are hereby incorporated by
reference into this application in order to more fully describe the
state of the art as known to those skilled therein as of the date
of the invention described and claimed herein.
[0078] This invention is illustrated in the Experimental Details
section which follows. These sections are set forth to aid in an
understanding of the invention but are not intended to, and should
not be construed to, limit in any way the invention as set forth in
the claims which follow thereafter.
Example 1
Generation of Transgenic Mice with Targeted (RAGE) in Neurons
[0079] This paper describes a means of making transgenic mice with
targeted overexpression of RAGE in neurons using the PDGF B-chain
promoter and the cDNA for human full-length RAGE. The mice, termed
Tg PD-RAGE, which have been produced provide a model system for
determining the consequences of heightened RAGE expression in
neurons, and could serve as an important model system to test RAGE
blockers, either inhibitors of ligand-receptor interaction or
inhibitors of RAGE-dependent intracellular signalling.
Cross-breeding of Tg PD-RAGE with other animals, such as those
expressing a transgene causing overexpression of mutant amyloid
precursor protein (resulting in increased production of
amyloid-beta peptide) provide a model system to assess the effects
of RAGE in an A.beta.-rich environment in the brain relevant to
Alzheimer's disease. In addition, isolation and culture of
embryonic neurons from Tg PD-RAGE mice allows study of the
consequences of increased levels of RAGE in vitro in actual
neurons. These are several examples of how Tg PD-RAGE mice can be
used to assess the contribution of RAGE, analyzed according to in
vitro and in vivo systems, to situations potentially relevant to
human disease.
Introduction
[0080] Receptor for Advanced Glycation Endproducts (RAGE) is a
multiligand member of the immunoglobulin superfamily of cell
surface molecules.sup.1. In the central nervous system, RAGE is
present at high levels in early development, but then its
expression falls off with maturity.sup.2,3. However, with
development of a pathology in the central nervous system, such as
Alzheimer's disease (AD), RAGE expression increases to high
levels.sup.4. Similarly, in murine models of stroke RAGE expression
also increases. This suggests that RAGE may participate in the host
response, though it is not clear if its participation would be
favorable or deleterious to the outcome.
[0081] There are several ways to dissect the contribution of RAGE
in physiologic and pathophysiologic settings. One method which we
have used extensively is administration of soluble RAGE, the
extracellular domain, which serve as a decoy for ligands seeking
out cell surface receptor, and anti-RAGE.sup.5-7. However these
reagents are principally useful in tissues served by the systemic
circulation which provides the means for delivery. Tissues behind
the blood-brain barrier, such as neurons (e.g., the entire central
nervous system) pose a more difficult problem since macromolecules
do not have ready access under moat conditions. For this reason, we
sought to create genetic models to dissect the contribution of
RAGE. In this context, there are three general approaches:
[0082] Targeted over-expression of wild-type RAGE wherein the
transgenic non-human animal would exhibit exaggerated effects of
RAGE in the particular tissue/cell under study (the RAGE is
overexpressed in a tissue specific manner.
[0083] Targeted overexpression of a mutant form of the receptor in
which the RAGE cytosolic tail has been deleted. This form of the
molecule functions as a dominant-negative, thereby blocking the
effects of ligand engagement of wild-type RAGE.
[0084] Deletion of the RAGE gene by homologous recombination (this
can also be carried out using conditional strategies to achieve
tissue-specific knockout. (Also termed, a RAGE knockout transgenic
non-human animal.)
[0085] This report describes the generation of mice with targeted
overexpression of human RAGE in neurons using the PDGF B-chain
promoter, termed Tg PD-RAGE mice. In addition, we describe the
effect of stroke on Tg PD-RAGE mice, and the results of crossing Tg
PD-RAGE mice with animals overexpressing a mutant form of amyloid
precursor protein (APP) which causes increased production of
amyloid-beta peptide (A.beta.).
Methods
[0086] Construction of the Transgene and Making the Transgenic (Tg)
mice.
[0087] The platelet-derived growth factor (PDGF) B-chain promoter
was used to drive overexpression of RAGE in neurons of the central
nervous system of transgenic (Tg) mice.sup.8. Transgene constructs
were prepared using a previously described vector.sup.9,10.
Briefly, the CMV immediate/early promoter was excised from the
commercial expression vector pCI (Promega, Madison Wis.), and
replaced with an oligonucleotide polylinker. The PDGF B-chain
promoter fragment was mobilized as an XbaI fragment.sup.8 and
cloned into a unique SpeI site designed within the synthetic
linker. The full-length human RAGE cDNA was inserted into the NotI
site of the original polylinker. A schematic representation of this
construct is shown in FIG. 1A (upper panel). An .apprxeq.3 kb
fragment containing the promoter, cDNA and required other sequences
was then excised from the plasmid backbone as a PvuI fragment (FIG.
1B, lower panel) and microinjected mouse B6CBAF.sub.i/J oocytes.
The latter were implanted into pseudopregnant females and mated
with B6CBAP.sub.i/J males resulting in the generation of
independent founders. Breeding of these mice demonstrated germ-line
transmission and was used to produce lines of animals termed Tg
PD-RAGE.
[0088] Founders were initially identified by Southern blotting
performed on DNA extracted from mouse tails. DNA was digested, run
on agarose gels, and hybridized with .sup.32P-labelled cDNA for
human RAGE. Tails were digested with proteinase K (500 .mu.g/ml) in
digestion buffer (50 mM Trig, pH 8.0, 100 mM EDTA, 0.5% SDS) at
55.degree. C. for overnight. Then, purified DNA was cleaved with
EcoRI overnight at 37.degree. C. Labelling of the probe was done
using the Stratagene's Probe Labeling Kit.TM.. Autoradiography was
then performed.
[0089] Subsequent screening of progeny was by PCR using the
following primers: 5'-AGCGGCTGGAATGGAAACTGAACA-3' (SEQ ID NO:7) and
3'-GAAGGGGCAAGGGCACACCATC-5' (SEQ ID NO:8). Total RNA was isolated
using Trizol.RTM., and RT-PCR was performed with the following
thermocycling parameters: 30 sec for each cycle consisting of
incubations at 95.degree. C. for 20 sec, 57.degree. C. for 30 sec
and 72.degree. C. for 1 sec for a total of 35 cycles. Products were
analyzed by agarose gel electrophoresis (1%) and visualized by
ethidium bromide staining under ultraviolet illumination. The size
of the RAGE amplicon with these primers corresponded to 701 bp.
[0090] Northern and immunoblotting utilized the same procedures as
above, except that tissue was homogenized in the presence of Trizol
(RNA) or in homogenization buffer (Tris/HCl, 10 mM, pH 7.4; NaCl,
100 mM; phenylmethylsulfonylfluoride, 100 .mu.g/ml; EDTA, 1 mM;
aprotonin, 1 .mu.g/ml). Note that immunoblotting and immunostaining
of brain tissue from Tg PD-ABAD mice used anti-human RAGE
IgG.sup.7.
Characterization of RAGE Expression in Tg PD-RAGE Mice.
[0091] Northern analysis was performed on total RNA isolated from
cerebral cortex, hippocampus and cerebellum. RNA was isolated using
Trizol.RTM. followed by electrophoresis on 0.8% agarose gels (30
.mu.g was applied to each lane), transfer to nitrocellulose
membranes, and hybridization with .sup.32P-labelled human RAGE
cDNA. The RAGE cDNA was labelled by as above.
[0092] Western blotting was performed on protein extracts of brain
subregions. Proteins were extracted from minced pieces of brains by
exposing the tissue to lysis buffer (Tris/HCl, 20 mM; pH 7.4;
Triton X-100, 1%; phenylmethylsulfonylfluoride, 2 mM; EDTA, 1 mM,
aprotonin, 10 .mu.g/ml; leupeptin, 10 .mu.g/ml) using a ratio of 1
ml of buffer per 0.5 .mu.m of tissue. Extracts were then boiled in
reducing SDS-sample buffer, and applied to SDS-PAGE according to
Laemmli.sup.11.
[0093] Immunostaining was performed on paraformaldehyde (4%)-fixed,
paraffin embedded sections (6 .mu.m) of mouse brains prepared
according to standard methods.sup.4-7. The sections were
deparaffinized and dehydrated, and then stained with rabbit
anti-human RAGE IgG, (50 .mu.g/ml) followed by goat anti-rabbit
biotin-conjugated IgG and ExtrAvidin-conjugated with alkaline
phosphatase (Biotin ExtrAvidin.RTM. kit; Sigma, St. Louis Mo.).
Preparation of anti-RAGE IgG, using recombinant soluble RAGE as the
immunogen, has been described.sup.4-7.
Induction of Stroke in Tg PD-RAGE Mice.
[0094] Functional consequences of overexpression of RAGE were first
assessed in response to ischemic stress, the transient middle
cerebral artery occlusion model. Murine stroke model Mice
(C57BL6/J, male) were subjected to stroke according to previously
published procedures.sup.12. Following anesthesia, the carotid
artery was accessed using the operative approach previously
described in detail.sup.13, including division/coagulation of the
occipital and pterygopalatine arteries to obtain improved
visualization and vascular access. A nylon suture was then
introduced into the common carotid artery, and threaded up the
internal carotid artery to occlude the origin of the right middle
cerebral artery (MCA). Nylon (polyamide) suture material was
obtained from United States Surgical Corporation (Norwalk, Conn.),
and consisted of 5.0 nylon/13 mm length for 27-36 g mice, and 6.0
nylon/12 mm length for 22-26 g mice. After 45 minutes of occlusion,
the suture was withdrawn to achieve a reperfused model of stroke.
Although no vessels were tied off after the suture was removed, the
external carotid arterial stump was cauterized to prevent frank
hemorrhage.
[0095] Measurements of relative cerebral blood flow were obtained
as previously reported.sup.12-15 using a straight laser doppler
flow probe placed 2 mm posterior to the bregma, and 6 mm to each
side of midline using a stereotactic micromanipulator, keeping the
angle of the probe perpendicular to the cortical surface. These
cerebral blood flow measurements, expressed as the ratio of
ipsilateral to contralateral blood flow, were obtained at baseline,
and immediately prior to MCA occlusion, 45 minutes after MCA
occlusion, and at several time points after withdrawal of the
occluding suture.
[0096] Measurement of Cerebral Infarction Volumes: After 24 hours,
animals were euthanized and their brains rapidly harvested. Infarct
volumes were determined by staining aerial cerebral sections with
triphenyl tetrazolium chloride and performing computer-based
planimetry of the negatively (infarcted) staining areas to
calculate infarct volume (using NIH image software).
[0097] Neurological Exam: Prior to giving anesthesia, mice were
examined for neurological deficit 23 h after reperfusion using a
four-tiered grading system: a score of 1 was given if the animal
demonstrated normal spontaneous movements; a score of 2 was given
if the animal was noted to be turning towards the ipsilateral side;
a score of 3 was given if the animal was observed to spin
longitudinally (clockwise when viewed from the tail); and, a score
of 4 was given if the animal was unresponsive to noxious stimuli.
This scoring system has been previously described in
mice.sup.12-14, and is based upon similar scoring systems used in
rats.sup.14. Immunostaining of cerebral cortex following induction
of stroke in wild-type mice was performed as described above using
a rabbit polyclonal antibody made using purified recombinant murine
ABAD as the immunogen. Quantitation of microscopic images was
accomplished with the Universal Imaging System.
[0098] Cross-Breeding of Tg PD-RAGE Mice with Tg hAPP Mice.
[0099] Tg mice overexpressing an alternatively spliced hAPP
minigene that encodes hAPP695, hAPP751, and hAPP770 bearing
mutations linked to familial AD (V717F, R670M/N671L) have been
produced by Dr. Lennart Mucks.sup.17, and provided to us for use in
cross-breeding studies with Tg PD-RAGE mice. In these mice,
expression of the transgene is also driven by the PDGF B-chain
promoter. Cross-breeding was performed and double-transgenic mice
expressing both hAPP and PD-RAGE transgenes were identified with
specific primers. The primers for the hAPP transgene were:
5'-GACAAGTATCTCGAGACACCTGGGGATGAG-3' (SEQ ID NO:9) and
3'-AAAGAACTTGTAGGTTGGATTTTCGTACC-5' (SEQ ID NO:10). PCR conditions
for the amplifying the hAPP transgene were the same as those
described above, and the size of the amplicon was 1169 bp.
Characterization of Tg PD-RAGE/hAPP mice.
[0100] Mice were anesthetized according to standard procedures and
then flush-perfused transcardially with solution containing NaCl
(0.9%). Brains will then be rapidly removed and divided sagitally.
One hemibrain was postfixed in phosphate-buffered saline (PBS)
containing paraformaldehyde (4%; pH 7.4) at 4.degree. C. for 48 hrs
prior to vibratome sectioning. Hemibrains were stored in
cryoprotectant medium (phosphate-buffered saline containing
glycerin and ethylene glycol) until sectioning. This portion of the
brain was employed for studies of neuronal integrity and
degeneration. There is ample evidence that loss of
synaptophysin-immunoreactivity in presynaptic terminals is
associated with AD brain, a marker which correlates with extent of
cognitive impairments.sup.18-23. Additionally, immunoreactivity for
Microtubule-associated protein (MAP)-2 was examined as a marker of
neuronal cell bodies and dendrites, as a significant decrease of
MAP-2 immunoreactive dendrites has been observed for example, in
brains of patients with neurodegeneration subsequent to HIV-1
encephalitis.sup.24.
[0101] Hemibrains were subjected to sagittal sectioning employing a
Leica Vibratome.RTM. 1000E. Sections, 40 .mu.m thick, were prepared
and collected into the wells of 12-well tissue culture plates in
cryoprotectant medium and stored at -20.degree. C. until
immunostaining was performed. Two sections per mouse were randomly
selected for further study, based on full integrity of the sample,
i.e., clearly delineated neocortex, and CA1, CA2 and CA3 were
completely intact. Prior to immunohistochemistry, free-floating
sections were placed individually in wells of 24-well tissue
culture plates and washed twice in phosphate-buffered saline (PBS;
pH 7.4; containing calcium/magnesium). Sections were then
permeabilized in PBS containing Triton X-100 (0.2%) for 20 min at
room temperature. Sections were stained with antibodies to perform
assessment of neuronal integrity. Anti-synaptophysin IgG
(Boehringer) was employed as a marker of presynaptic terminals.
Anti-MAP-2 IgG (Boehringer) was employed as a marker of neuronal
cell bodies/dendrites. The appropriate nonimmune IgG was employed
as a control (Boehringer Mannheim). After appropriate blocking
steps, primary antibodies were incubated with sections and then
washed in PBS. FITC-labeled secondary antibodies (Vector system;
ABC) were employed to visualize sites of primary antibody binding.
After washing, sections were mounted using Vectashield on glass
slides and then coverslips placed atop the sections. Sections will
then be kept in the dark at 4.degree. C., for no more than two
weeks prior to analysis.
[0102] Semiquantitative evaluation of neuronal integrity was
performed using laser scanning confocal microscopy. Neuronal
integrity was assessed in the neocortex and pyramidal cell layer of
the hippocampus (CA1 subfield) in six sections per mouse (two for
each antibody marker). For each mouse, 4-8 confocal images
(3-4/section) of the neocortex, and 2-4 confocal images
(1-2/section) of the hippocampal CA1 subfield, each covering an
area of 210.times.140 .mu.m, were obtained. Under 60.times., oil
immersion, the sample was focused and iris and gain levels adjusted
to obtain images with a pixel intensity within a linear range. Each
final image was processed sequentially in Lasersharp. Digitized
images were then transferred to a Macintosh computer using Adobe
Photoshop, JPEG compression and analyzed with NIH Image. The area
of the neuropil occupied by MAP-2-labeled dendrites or by
synaptophysin-labeled presynaptic terminals was quantified and
expressed as a percentage of the total image area as
described.sup.24. Final analysis of digitized images for area
neuropil occupied was determined by two independent investigators.
Mean t standard deviation is reported for each section. Control
sections were studied under conditions in which primary antibody
was omitted, and no signal was observed with secondary antibody
alone.
[0103] Immunostaining of mouse brain for other markers employed
commercially available goat antibody to murine macrophage-colony
stimulating factor (goat anti-M-CSF IgG; 10 .mu.g/ml; Santa Cruz),
rabbit antibody to activated caspase 3 (50 .mu.g/ml; PharMingen),
and mouse monoclonal antibody to phosphorylated tau (ATB; 10 mg/ml;
Immunogenetics). In each case, the immunostaining protocol used
standard techniques according to the manufacturer's instructions.
Rabbit anti-murine Interleukin (IL) 6 IgG was provided by Dr.
Gerald Fuller (University of Alabama Medical Center, Birmingham)
and has been used in previous studies.sup.25. Sections were
incubated with primary antibodies overnight at 4.degree. C.,
followed by blocking with appropriate antisera and addition of
biotin-conjugated goat anti-rabbit, goat anti-mouse or mouse
anti-goat IgG (1:25 dilution) for 30 min at 37.degree. C. Then
ExtrAvidin.RTM. conjugated to peroxidase or to alkaline phosphatase
(1:25 dilution) was added for 25 min at 37.degree. C. Slides were
then washed and developed with 3-amino-9-ethyl carbazole or fast
red. Sections were viewed in an Olympus microscope, and images were
quantified using the Universal imaging system.
[0104] Activation of the transcription factor NF-kB was studied in
brains of mice and in neurons cultured from this tissue (see
below). Nuclear extracts were prepared according to the method of
Dignam at al..sup.26, and were incubated with .sup.32P-labelled
double stranded consensus oligonucleotide probe for NF-kB (Santa
Cruz) followed by polyacrylamide gel electrophoresis and
autoradiography. These methods have been described previously using
brain tissue and cultured cells as the samples for preparation of
nuclear extracts.sup.4.
Isolation and Characterization of Neurons from Tg PD-RAGE mice.
[0105] Brains of E16-18 mouse embryos were processed by a
modification of a previously described method.sup.27. In brief,
Embryos were washed in ethanol (75%), transferred to a dish with
sterile phosphate-buffered saline (PBS) at 4.degree. C. under a
tissue culture hood. Two embryos were dissected at a time immersed
in Neurobasal Medium (GIBCO) with Nadi (22 mM), NaHCO.sub.3 (4.4
mM), penicillin (50 units/ml) and streptomycin (50 .mu.g/ml). The
embryo tail was removed and analyzed by PCR to determine genotype
(as above). Cerebral cortex was dissected free from the cerebellum
and brainstem, sliced into 1 mm pieces, and transferred to 1.5 ml
eppendorf tubes in the above medium. The tube was centrifuged at
400 rpm, the pellet was washed in PBS, and resuspended in PBS.
Then, trypsin (0.25%; 0.5 ml) and DNAse (250 units/ml) were added
and the incubation was continued for 15 min at 37.degree. C. with
gentle shaking. The mixture was decanted, washed twice in PBS by
inverting the tube and gently spinning at 400 rpm for 5 min.
Neurons were cultured in growth medium (Neurobasal Medium with B27,
2%, L-glutamine, 2 mM, penicillin, 50 units/ml, streptomycin, 50
.mu.g/ml) in wells coated with poly-L-lysine. Neurons were
identified immunocytochemically using antibody to neurofilament
(Sigma) and the methods for immunostaining described above.
[0106] Cultures of neurons were exposed to preformed A.beta.(1-42)
fibrils for 5 hrs at 37.degree. C. A.beta.(1-42) synthetic peptide
was purchased from QCB, and was incubated for 5 days at 37.degree.
C. to allow fibril formation to occur. The presence of fibrils was
confirmed by electron microscopy. Fibril preparations were then
frozen (-20.degree. C.) until use. Just prior to an experiment,
fibril preparations were thawed, vertexed, and then added to
culture medium to a final concentration of 0.5 .mu.M for 5 hrs
(NF-kB activation) or 30-40 hrs (detection of activated caspase 3)
at 37.degree.. Nuclear extracts were prepared and EMSA was
performed as above. Where indicated, anti-RAGE IgG was added during
incubation of A.beta. fibrils with the cells.
[0107] Caspase 3 activity was studied using a kit from
Clontech.
Results
Identification of Tg PD-RAGE Mice.
[0108] Southern analysis identifying three Tg PD-RAGE founders is
shown in FIG. 2. These mice were used to generate lines of Tg
PD-RAGE mice in whom the progeny were identified by PCR using the
primers described in the methods section. An example of PCR
detection of positive founders, versus negative non-Tg animals is
shown in FIG. 3.
Characterization of Tg PD-RAGE Mice.
[0109] Expression of the transgene in the brain was determined by
Northern analysis of total RNA extracted from cerebral cortex with
.sup.32P-labelled cDNA for human RAGE (FIG. 4A). An intense band
was observed in Tg PD-RAGE mice, but not in nontransgenic
littermate controls. Similarly Western analysis was performed on
protein extracts of cerebral cortex from transgenic mice using
antibody to the extracellular domain of recombinant human RAGE.
Again, a strong band of immunoreactivity migrating above the 46 kDa
molecular weight marker confirmed the presence of high levels of
RAGE antigen in brains of Tg PD-RAGE mice compared with
nontransgenic littermate controls (FIG. 4B). Immunoblotting was
then performed on brain subregions, including cerebral cortex,
hippocampus and cerebellum, with anti-RAGE IgG (FIG. 5). In Tg
PD-RAGE mice, intense immunoreactive bands were seen in cerebral
cortex and hippocampus, compared with lower levels of transgene
expression in the cerebellum. Immunostaining with anti-RAGE IgG
confirmed that the increased levels of RAGE in Tg PD-RAGE animals
were in neurons (FIG. 6A-B). These data indicate that Tg PD-RAGE
mice provide a model system in which neurons of the brain,
especially cerebral cortex and hippocampus express high levels of
RAGE.
[0110] To examine consequences of enhanced neuronal RAGE expression
for ischemic stress experiments were performed in a murine model of
transient occlusion of the middle cerebral artery (FIG. 7). Tg
PD-RAGE mice, as well as nonTg littermate controls weighed
.apprxeq.26 grams and were .apprxeq.10 wks old. Neurologic deficit
score, evaluated at the 24 hr point, was reduced in Tg PD-RAGE mice
compared with nonTg littermates. The volume of infarcted cerebral
tissue was reduced by .apprxeq.50% in Tg mice (FIG. 7;
p<0.05).
Characterization of Tg PD-RAGE/hAPP Mice.
[0111] The increased expression of RAGE in AD brain, compared with
age-matched non-demented brain, suggested that the receptor might
be associated with AD pathology. Consistent with this hypothesis,
our pilot studies with Tg hAPP mice displayed increased levels of
RAGE in cerebral cortex by 4 months of age, which is prior to
plaque formation. Tg hAPP mice are especially useful for studies to
assess the effect of introduction of the PD-RAGE transgene since
they have been characterized in previous studies with respect to
neuropathologic and electrophysiologic properties.
[0112] If RAGE-A.beta. interaction promoted neuronal stress, we
reasoned that expression of high levels of RAGE at early times in
the brains of animals expressing the hAPP transgene might result in
magnified cell stress and cytotoxicity (the transgenic model
introduces higher levels of RAGE expression than were present in Tg
hAPP mice alone, and thus, potentially represents a model of
exaggerated effects of RAGE due to overexpression of the receptor).
Cross-breeding studies were performed and double transgenic mice
were identified by PCR using primers specific for the PD-RAGE
transgene and the hAPP transgene. Results of a representative PCR
analysis are shown in FIG. 8 demonstrating amplicons for both the
PD-RAGE and hAPP genes in the double-transgenic animals versus
single transgenics and nontransgenic littermate controls. The
double transgenic mice have been termed Tg PD-RAGE/hAPP mice.
[0113] Double transgenic mice were observed for three-four months
and evidence of neuronal stress was then analyzed by studying
expression of M-CSF (FIGS. 9A, 9B1-B3, 9C) and IL-6 (FIGS. 10A,
10B1-B3, 10C), and activation of NP-kB (FIG. 11). Northern analysis
of cerebral cortex showed increased levels of transcripts for M-CSF
in Tg PD-RAGE/hAPP mice compared with single transgenics (Tg hAPP
and Tg PD-RAGE) and nonTg littermate controls (FIG. 9A).
Immunostaining with anti-M-CSF IgG confirmed that the increase in
M-CSF antigen was predominately in neurons, and that
double-transgenics showed elevated levels of antigen compared with
the other groups (FIGS. 9B1, 9B2, 9B3 and 9C). Similar results were
observed with respect to increased expression of IL-6 transcripts
and antigen (FIG. 10A, 10B1-B3, 10C)). Since activation of NF-kB is
associated with cellular stress responses and can underlie
expression of M-CSF and IL-6, we analyzed nuclear translocation of
NF-kB in nuclear extracts prepared from brains of the transgenic
mice by EMSA (FIG. 11). Analysis of double transgenic mice
invariably displayed a strong gel shift band, whose intensity
varied somewhat in the different animals, whereas weak/absent bands
were seen in the control group and single transgenics.
[0114] These data were consistent with increased neuronal stress in
Tg PD-RAGE/hAPP mice, but did not indicate whether the outcome of
this stress would be neuroprotection or neurotoxicity. To analyze
this situation neuropathologic studies were performed, and study of
markers more clearly associated with toxicity, such as activated
caspase 3, was undertaken. Immunostaining of hippocampus (lacunosum
molecular layer) from double transgenic mice (age 3-4 months) with
antibody to synaptophysin demonstrated a reduction in the area of
neuropil occupied by synaptophysin-labeled presynaptic terminals
(FIG. 12). Similar studies with antibody to MAP-2 showed a
reduction in the area of neuropil occupied by MAP-2-labeled
dendrites (FIG. 13). Although stereologic studies will be required
to determine actual neuronal loss, these results are consistent
with evidence of neurotoxicity. Consistent with this impression,
analysis of older double transgenic mice (8-9 months of age) showed
increased staining with an antibody selective for the activated
form of caspase 3 (FIGS. 14A1-4, 14B) and phosphorylated tau (AT8)
(FIGS. 15A1-A4, 15B) in brains of double transgenic mice compared
with the other groups.
Culture of neurons from Tg PD-RAGE mice.
[0115] Neuronal cultures were made from the cerebral cortex from
E16 mouse embryos. These cultures were >90% neurons based on
staining with anti-neurofilament antibody. Cultured neurons
displayed high levels of RAGE expression based on immunoblotting
(FIG. 16). Such neuronal cultures were incubated with preformed
A.beta.(1-40) fibrils (0.5 .mu.M) for 2 hrs, and then nuclear
extracts were prepared for EMSA using consensus probe for NF-kB. A
gel shift band was observed in neuronal cultures from Tg PD-RAGE
mice, but such a band was either not seen or present at much
reduced intensity with samples from nontransgenic littermate
control mice (FIG. 17A). That this was due to A.beta.-RAGE
interaction was confirmed by the dose-dependent inhibitory effect
of anti-RAGE IgG, but not nonimmune IgG (FIG. 17B). To determine
whether neurons overexpressing RAGE exposed to A.beta. fibrils were
being forced down a pathway of enhanced toxicity evidence of
activated caspase 3 was sought. After 30-40 hrs of exposing A.beta.
fibrils to neurons from Tg PD-RAGE mice, increased caspase 3
activity was detected (FIG. 18). In contrast, under these
conditions, neurons form nonTg littermates did not display
increased caspase 3 activity.
Discussion
[0116] We have described the generation of Tg PD-RAGE mice which
display increased expression of full-length RAGE in neurons. The
use of these mice to analyze the contribution of RAGE to cellular
responses in vitro and in vivo can be summarized according to three
general categories:
[0117] 1) analysis of neurons cultured from embryos of Tg PD-RAGE
mice. Since neurons are nondividing cells and can only be
transfected successfully with viral-based systems (which can alter
cellular properties themselves), the cultured neurons from Tg
PD-RAGE mice provide an unique system in which neurons overexpress
human RAGE. These cells can be used to analyze the consequences of
RAGE-ligand interaction for neuronal function, as shown by the
activation of NP-kB and activation of caspase 3 in the above
studies.
[0118] 2) Tg PD-RAGE mice can be used to directly assess the effect
of RAGE overexpression in settings such as, but not limited to,
stroke (described above), viral/bacterial infections, other models
of brain inflammation (such as experimental autoimmune
encephalitis) etc.
[0119] 3) Tg PD-RAGE mice can be crossbred with other transgenic
animals, such as Tg hAPP to determine the consequences of RAGE
overexpression in an environment in which the other transgene
creates an unique environment in the brain. For example, the Tg
hAPP mouse results in increased levels of A.beta.. In this setting,
the consequences of increased levels of A.beta. in the context of
neurons bearing elevated levels of RAGE can be studied. Another
example would be cross-breeding of Tg PD-RAGE mice with mice
deficient in the gene for apolipoprotein E.sup.28, resulting in a
model of accelerated atherosclerosis potentially with an
exaggerated effect of RAGE.
[0120] In each case, the in vitro and in vivo systems based on Tg
PD-RAGE mice or cells derived from them are ideal for studying RAGE
inhibitors, as well as for dissecting contributions of RAGE to
physiologic/pathophysiologic outcomes.
Example 2
Induction of Transient Middle Cerebral Artery in RAGE Transgenic
Mice and Use of this Transgenic Mouse Model for Stroke in
Humans
Methods:
Induction of Transient Middle Cerebral Artery Occlusion in the
Mouse
Induction of Stroke in Tg PD-RAGE Mice.
[0121] Functional consequences of overexpression of RAGE were first
assessed in response to ischemic stress, the transient middle
cerebral artery occlusion model. Murine stroke model Mice
(C57BL6/J, male) were subjected to stroke according to previously
published procedures. Following anesthesia, the carotid artery was
accessed using the operative approach previously described in
detail.sup.33, including division/coagulation of the occipital and
pterygopalatine arteries to obtain improved visualization and
vascular access. A nylon suture was then introduced into the common
carotid artery, and threaded up the internal carotid artery to
occlude the origin of the right middle cerebral artery (MCA). Nylon
(polyamide) suture material was obtained from United States
Surgical Corporation (Norwalk, Conn.), and consisted of 5.0
nylon/13 mm length for 27-36 g mice, and 6.0 nylon/12 mm length for
22-26 g mice. After 45 minutes of occlusion, the suture was
withdrawn to achieve a reperfused model of stroke. Although no
vessels were tied off after the suture was removed, the external
carotid arterial stump was cauterized to prevent frank
hemorrhage.
[0122] Measurements of relative cerebral blood flow were obtained
as previously reported.sup.32-38 using a straight laser doppler
flow probe placed 2 mm posterior to the bregma, and 6 mm to each
side of midline using a stereotactic micromanipulator, keeping the
angle of the probe perpendicular to the cortical surface. These
cerebral blood flow measurements, expressed as the ratio of
ipsilateral to contralateral blood flow, were obtained at baseline,
and immediately prior to MCA occlusion, 45 minutes after MCA
occlusion, and at several time points after withdrawal of the
occluding suture.
Measurement of Cerebral Infarction Volumes:
[0123] After 24 hours, animals were euthanized and their brains
rapidly harvested. Infarct volumes were determined by staining
serial cerebral sections with triphenyl tetrazolium chloride and
performing computer-based planimetry of the negatively (infarcted)
staining areas to calculate infarct volume (using NIH image
software).
Neurological Exam:
[0124] Prior to giving anesthesia, mice were examined for
neurological deficit 23 h after reperfusion using a four-tiered
grading system: a score of 1 was given if the animal demonstrated
normal spontaneous movements; a score of 2 was given if the animal
was noted to be turning towards the ipsilateral side; a score of 3
was given if the animal was observed to spin longitudinally
(clockwise when viewed from the tail); and, a score of 4 was given
if the animal was unresponsive to noxious stimuli. This scoring
system has been previously described in mice.sup.32-34, and is
based upon similar scoring systems used in rats.sup.36.
Immunostaining of cerebral cortex following induction of stroke in
wild-type mice was performed as described above using a rabbit
polyclonal antibody made using purified recombinant murine ABAD as
the immunogen. Quantitation of microscopic images was accomplished
with the Universal Imaging System.
Results:
[0125] Transgenic mice overexpressing RAGE under control of the
platelet-derived growth factor promoter were subjected to transient
middle cerebral artery occlusion along with non-transgenic
littermates. Mice were 26-29 grams in weight and about 10 weeks
old. The volume of infarcted cerebral tissue was reduced about 50%
(P<0.05) in the transgenic mice compared with the controls (see
FIG. 19A shows the results of studies in all mice, and FIG. 19B
shows triphenyl tetrazolium chloride staining of selected cerebral
sections). It is important to note that glucose levels were
monitored in the animals before and after the ischemic episode,
because of the known effect of hyperlgycemic on infarct volume. The
animals remained normoglycemic throughout the procedure. These data
indicate that overexpression of RAGE in neurons has a
neuroprotective effect. Thus, it would be important to test
potential RAGE inhibitors in such an animal to determine if they
antagonized this protective property of the receptor. Figure
legend: for the figure which you SHOULD send a messenger to pick
up. Induction of stroke in transgenic mice overexpressing RAGE on
the platelet-derived growth factor promoter: cerebral infarct
volume (FIG. 19A) and results of triphenyl tetrazolium chloride
staining of selected cerebral sections (FIG. 19B).
REFERENCES
[0126] 1. Schmidt A-M, Yan S-D, Wautier J-L, Stern D M: Activation
of RAGE: a mechanism for chronic dysfunction in diabetic
vasculopathy and atherosclerosis. Circ Res 1999; 84:489-497 [0127]
2. Mori O, Brett J, Nagashima M, Nitecki D, Morser 3, Stern D M,
Schmidt A M: RAGE is a cellular binding site for amphoterin:
mediation of neurite outgrowth and co-expression of RAGE and
amphoterin in the developing nervous system. J Biol Chem 1995;
270:25752-25761 [0128] 3. Brett J, Schmidt A-M, Zou Y-S, Yan S-D,
Weidman E, Pinsky D J, Neeper M, Przysiecki M, Shaw A, Migheli A,
Stern D M: Tissue distribution of the receptor for advanced
glycation endproducts (RAGE): expression in smooth muscle, cardiac
myocytes, and neural tissue in addition to vasculature. Am J Pathol
1993; 143:1699-1712 [0129] 4. Yan S-D, Chen X, Chen M, Zhu H, Roher
A, Slattery T, Zhao L, Nagashima M, Morser J, Migheli A, Nawroth P,
Stern D M, Schmidt A-M: RAGE and amyloid-beta peptide neurotoxicity
in Alzheimer's disease. Nature 1996; 382:685-691 [0130] 5. Park L,
Raman K, Lee K, Lu Y, Ferran L, Chow W--S, Stern D, Schmidt A-M:
Suppression of accelerated diabetic atherosclerosis by soluble
receptor for AGE (sRAGE). Nature Med 1998; 4:1025-1031 [0131] 6.
Hofmann M, Drury S, Caifeng F, Qu W, Lu Y, Avila C, Kambhan N,
Slattery T, McClary J, Nagashima M, Morser J, Stern D, Schmidt A-M:
RAGE mediates a novel proinflammatory axis: the cell surface
receptor for S100/calgranulin polypeptides. Cell 1999; 97:889-901
[0132] 7. Ian S-D, Zhu H, Zhu A, Golabek A, Roher A, Yu J, Soto C,
Schmidt A-M, Stern D M, Kindy M: Receptor-dependent cell stress and
amyloid accumulation in systemic amyloidosis. Nat Med 2000;
6:643-651 [0133] 8. Sasahara M, Fries J, Raines E, Gown A, Westrum
L, Frosch M, Bonthron D, Ross R, Collins T: PDGF B-chain in neurons
of the central nervous system, posterior pituitary and in a
transgenic model. Cell 1991; 64:217-227 [0134] 9. Kang D, Saitoh T,
Chen X, Xia Y, Maslian E, Hansen L, Thomas R, Thal L, Katzman R:
Genetic association of LRP with late-onset Alzheimer's disease.
Neurology 1997; 49:56-61 [0135] 10. Berezovska O, Frosch M, McLean
P, Knowles R, Koo E, Kang D, Shen J, Lu F, Lux 3, Tonegawa S, Hyman
B: The Alzheimer-related gene presenilin 1 facilitates notch 1 in
primary mammalian neurons. Molec Brain Res 1999; 69:273-280 [0136]
11. Laemmli U: Cleavage of structural proteins during the assembly
of the head of bacteriophage T4. Nature 1970; 227:680-685 [0137]
12. Huang J, Kim L, Mealey R, March H, Zhang A, Tenner E, Connolly
E, Pinsky D: Neuronal protection in stroke by an sLex-glycosylated
complemetn inhibitory protein. Science 1999; 285:595-599 [0138] 13.
Connolly E S, Winfree C J, Stern D M, Solomon R A, Pinsky D J:
Procedural and strain-related variables significantly affect
outcome in a murine model of focal cerebral ischemia. Neurosurg
1996; 38:523-532 [0139] 14. Connolly E S J, Winfree C J, Springer T
A, Naka Y, Liao H, Yan S D, Stern D M, Solomon R A, Gutierrez-Ramos
J-C, Pinsky D J: Cerebral protection in homozygous null ICAM-1 mice
after middle cerebral artery occlusion. Role of neutrophil adhesion
in the pathogenesis of stroke. J Clin Invest 1996; 97:209-216
[0140] 15. Connolly E, Winfree C, Prestigiacomo C, Kim S, Choudhri
T, Hoh B, Naka Y, Solomon R, Pinsky D: Exacerbation of cerebral
injury in mice with express the P-selectin gene: identification of
P-selectin blockade as a new target for treatment of stroke. Circ
Res 1997; 81:304-310 [0141] 16. Bederson J B, Pitts L H, Tsuji M:
Rat middle cerebral artery occlusion: evaluation of the model and
development of a neurologic examination. Stroke 1986; 17:472-476
[0142] 17. Hsia A, Masliah E, McConlogue L, Yu G-Q, Tatsuno G, Hu
K, Kholodenko D, Malenka R, Nicoll R, Mucke L: Plaque-independent
disruption of neural circuits in Alzheimer's disease mouse models.
Proc Natl Acad Sci (USA) 199996:3228-3233 [0143] 18. Terry R,
Masliah E, Salmon D, Butters N, DeTeresa R, Hill R, Hansen L,
Katzman R: Physical basis of cognitive alterations in Alzheimer
disease: synapse loss is the major correlate of cognitive
impairment. Ann Neurol 1991; 30:572-580 [0144] 19. Zhan S,
Beyreuther K, Schmitt H: Quantitative assessment of synaptophysin
immunoreactivity of the corticla neuropil in various
neurodegenerative diseases with dementia. Dementia 1993; 4:66-74
[0145] 20. Dickson D, Crystal H, Bevona C, Honer W, Vincent I,
Davies P: Correlation of synaptic and pathological markers
incognition in the elderly. Neurobiol Aging 1995; 16:285-304 [0146]
21. Sze C, Troncoso J, Kowas C, Mouton P, Price D, Martin J: Loss
of presynaptic vesicle protein synaptophysin in hippocampus
correlates with cognitive decline in Alzheimer disease. J
Neuropathol Exp Neurol 1997; 56:933-944 [0147] 22. Samuel W, Alford
M, Hofstetter C, Hansen L: Dementia with Lewy bodies versus pure
Alzheimer disease: differences in cognition, neuropathology,
cholinergic dysfunction, and synapse density. J Neuropathol Exp
Neurol 1997; 56:499-508 [0148] 23. Brown D, Risser R, Bigio E,
Tripp P, Stiegler A, Welch E, Eagan K, Hladik C, White C:
Neocortical synatpic density and Braak stage in Lewy body variant
of Alzheimer disease. J Neuropathol Exp Neurol 1998; 58:955-960
[0149] 24. Masliah E, Achim C, Ge N, DeTeresa R, Terry R, Wiley C:
The spectrum of human immunodeficiency virus-associated neocortical
damage. Ann Neural 1992; 32:321-329 [0150] 25. Yan S-P, Tritto I,
Pinsky D J, Liao H, May L, Stern D M: Induction of interleukin 6
(IL-6) by hypoxia in vascular cells: central role of the binding
site for nuclear factor-IL-6. J Biol Chem 1995; 270:11463-11471
[0151] 26. Dignam J, Lebovitz R, Roeder R: Accurate transcription
initiation by RNA polymerase II in a soluble extract from isolated
mammalian nuclei. Nucl Acids Res 1983; 11:1475-1489 [0152] 27.
White A, Zheng H, Galatis D, Maher F, Heese L, Multhaup G,
Beyreuther K, Masters C, Cappai R: Survival of cultured neurons
from amyloid precursor protein knock-out mice against Alzheimer's
amyloid-3 toxicity and oxidative stress. J Neurosci 1998;
18:6207-6217 [0153] 28. Nakashima Y, Plump A, Raines E, Breslow J,
Roes R: ApoE-deficient mice develop lesions of all phases of
atherosclerosis throughout the arterial tree. Arterioscler Thromb
1994; 141:133-140
Sequence CWU 1
1
101416PRTBos taurus 1Met Ala Ala Gly Ala Val Val Gly Ala Trp Met
Leu Val Leu Ser Leu1 5 10 15Gly Gly Thr Val Thr Gly Asp Gln Asn Ile
Thr Ala Arg Ile Gly Lys 20 25 30Pro Leu Val Leu Asn Cys Lys Gly Ala
Pro Lys Lys Pro Pro Gln Gln 35 40 45Leu Glu Trp Lys Leu Asn Thr Gly
Arg Thr Glu Ala Trp Lys Val Leu 50 55 60Ser Pro Gln Gly Asp Pro Trp
Asp Ser Val Ala Arg Val Leu Pro Asn65 70 75 80Gly Ser Leu Leu Leu
Pro Ala Val Gly Ile Gln Asp Glu Gly Thr Phe 85 90 95Arg Cys Arg Ala
Thr Ser Arg Ser Gly Lys Glu Thr Lys Ser Asn Tyr 100 105 110Arg Val
Arg Val Tyr Gln Ile Pro Gly Lys Pro Glu Ile Val Asp Pro 115 120
125Ala Ser Glu Leu Met Ala Gly Val Pro Asn Lys Val Gly Thr Cys Val
130 135 140Ser Glu Gly Gly Tyr Pro Ala Gly Thr Leu Asn Trp Leu Leu
Asp Gly145 150 155 160Lys Thr Leu Ile Pro Asp Gly Lys Gly Val Ser
Val Lys Glu Glu Thr 165 170 175Lys Arg His Pro Lys Thr Gly Leu Phe
Thr Leu His Ser Glu Leu Met 180 185 190Val Thr Pro Ala Arg Gly Gly
Ala Leu His Pro Thr Phe Ser Cys Ser 195 200 205Phe Thr Pro Gly Leu
Pro Arg Arg Arg Ala Leu His Thr Ala Pro Ile 210 215 220Gln Leu Arg
Val Trp Ser Glu His Arg Gly Gly Glu Gly Pro Asn Val225 230 235
240Asp Ala Val Pro Leu Lys Glu Val Gln Leu Val Val Glu Pro Glu Gly
245 250 255Gly Ala Val Ala Pro Gly Gly Thr Val Thr Leu Thr Cys Glu
Ala Pro 260 265 270Ala Gln Pro Pro Pro Gln Ile His Trp Ile Lys Asp
Gly Arg Pro Leu 275 280 285Pro Leu Pro Pro Gly Pro Met Leu Leu Leu
Pro Glu Val Gly Pro Glu 290 295 300Asp Gln Gly Thr Tyr Ser Cys Val
Ala Thr His Pro Ser His Gly Pro305 310 315 320Gln Glu Ser Arg Ala
Val Ser Val Thr Ile Ile Glu Thr Gly Glu Glu 325 330 335Gly Thr Thr
Ala Gly Ser Val Glu Gly Pro Gly Leu Glu Thr Leu Ala 340 345 350Leu
Thr Leu Gly Ile Leu Gly Gly Leu Gly Thr Val Ala Leu Leu Ile 355 360
365Gly Val Ile Val Trp His Arg Arg Arg Gln Arg Lys Gly Gln Glu Arg
370 375 380Lys Val Pro Glu Asn Gln Glu Glu Glu Glu Glu Glu Arg Ala
Glu Leu385 390 395 400Asn Gln Pro Glu Glu Pro Glu Ala Ala Glu Ser
Ser Thr Gly Gly Pro 405 410 41521426DNABos taurus 2cggagaagga
tggcagcagg ggcagtggtc ggagcctgga tgctagtcct cagtctgggg 60gggacagtca
cgggggacca aaacatcaca gcccggatcg ggaagccact ggtgctgaac
120tgcaagggag cccccaagaa accaccccag cagctggaat ggaaactgaa
cacaggccgg 180acagaagctt ggaaagtcct gtctccccag ggagacccct
gggatagcgt ggctcgggtc 240ctccccaacg gctccctcct cctgccggct
gttgggatcc aggatgaggg gactttccgg 300tgccgggcaa cgagccggag
cggaaaggag accaagtcta actaccgagt ccgagtctat 360cagattcctg
ggaagccaga aattgttgat cctgcctctg aactcatggc tggtgtcccc
420aataaggtgg ggacatgtgt gtccgagggg ggctaccctg cagggactct
taactggctc 480ttggatggga aaactctgat tcctgatggc aaaggagtgt
cagtgaagga agagaccaag 540agacacccaa agacagggct tttcacgctc
cattcggagc tgatggtgac cccagctcgg 600ggaggagctc tccaccccac
cttctcctgt agcttcaccc ctggccttcc ccggcgccga 660gccctgcaca
cggcccccat ccagctcagg gtctggagtg agcaccgagg tggggagggc
720cccaacgtgg acgctgtgcc actgaaggaa gtccagttgg tggtagagcc
agaaggggga 780gcagtagctc ctggtggtac tgtgaccttg acctgtgaag
cccccgccca gcccccacct 840caaatccact ggatcaagga tggcaggccc
ctgccccttc cccctggccc catgctgctc 900ctcccagagg tagggcctga
ggaccaggga acctacagtt gtgtggccac ccatcccagc 960catgggcccc
aggagagccg tgctgtcagc gtcacgatca tcgaaacagg cgaggagggg
1020acgactgcag gctctgtgga agggccgggg ctggaaaccc tagccctgac
cctggggatc 1080ctgggaggcc tggggacagt cgccctgctc attggggtca
tcgtgtggca tcgaaggcgg 1140caacgcaaag gacaggagag gaaggtcccg
gaaaaccagg aggaggaaga ggaggagaga 1200gcggaactga accagccaga
ggagcccgag gcggcagaga gcagcacagg agggccttga 1260ggagcccacg
gccagacccg atccatcagc cccttttctt ttcccacact ctgttctggc
1320cccagaccag ttctcctctg tataatctcc agcccacatc tcccaaactt
tcttccacaa 1380ccagagcctc ccacaaaaag tgatgagtaa acacctgcca cattta
14263404PRTHomo sapiens 3Gly Ala Ala Gly Thr Ala Val Gly Ala Trp
Val Leu Val Leu Ser Leu1 5 10 15Trp Gly Ala Val Val Gly Ala Gln Asn
Ile Thr Ala Arg Ile Gly Glu 20 25 30Pro Leu Val Leu Lys Cys Lys Gly
Ala Pro Lys Lys Pro Pro Gln Arg 35 40 45Leu Glu Trp Lys Leu Asn Thr
Gly Arg Thr Glu Ala Trp Lys Val Leu 50 55 60Ser Pro Gln Gly Gly Gly
Pro Trp Asp Ser Val Ala Arg Val Leu Pro65 70 75 80Asn Gly Ser Leu
Phe Leu Pro Ala Val Gly Ile Gln Asp Glu Gly Ile 85 90 95Phe Arg Cys
Arg Ala Met Asn Arg Asn Gly Lys Glu Thr Lys Ser Asn 100 105 110Tyr
Arg Val Arg Val Tyr Gln Ile Pro Gly Lys Pro Glu Ile Val Asp 115 120
125Ser Ala Ser Glu Leu Thr Ala Gly Val Pro Asn Lys Val Gly Thr Cys
130 135 140Val Ser Glu Gly Ser Tyr Pro Ala Gly Thr Leu Ser Trp His
Leu Asp145 150 155 160Gly Lys Pro Leu Val Pro Asn Glu Lys Gly Val
Ser Val Lys Glu Gln 165 170 175Thr Arg Arg His Pro Glu Thr Gly Leu
Phe Thr Leu Gln Ser Glu Leu 180 185 190Met Val Thr Pro Ala Arg Gly
Gly Asp Pro Arg Pro Thr Phe Ser Cys 195 200 205Ser Phe Ser Pro Gly
Leu Pro Arg His Arg Ala Leu Arg Thr Ala Pro 210 215 220Ile Gln Pro
Arg Val Trp Glu Pro Val Pro Leu Glu Glu Val Gln Leu225 230 235
240Val Val Glu Pro Glu Gly Gly Ala Val Ala Pro Gly Gly Thr Val Thr
245 250 255Leu Thr Cys Glu Val Pro Ala Gln Pro Ser Pro Gln Ile His
Trp Met 260 265 270Lys Asp Gly Val Pro Leu Pro Leu Pro Pro Ser Pro
Val Leu Ile Leu 275 280 285Pro Glu Ile Gly Pro Gln Asp Gln Gly Thr
Tyr Ser Cys Val Ala Thr 290 295 300His Ser Ser His Gly Pro Gln Glu
Ser Arg Ala Val Ser Ile Ser Ile305 310 315 320Ile Glu Pro Gly Glu
Glu Gly Pro Thr Ala Gly Ser Val Gly Gly Ser 325 330 335Gly Leu Gly
Thr Leu Ala Leu Ala Leu Gly Ile Leu Gly Gly Leu Gly 340 345 350Thr
Ala Ala Leu Leu Ile Gly Val Ile Leu Trp Gln Arg Arg Gln Arg 355 360
365Arg Gly Glu Glu Arg Lys Ala Pro Glu Asn Gln Glu Glu Glu Glu Glu
370 375 380Arg Ala Glu Leu Asn Gln Ser Glu Glu Pro Glu Ala Gly Glu
Ser Ser385 390 395 400Thr Gly Gly Pro 41391DNAHomo sapiens
4ggggcagccg gaacagcagt tggagcctgg gtgctggtcc tcagtctgtg gggggcagta
60gtaggtgctc aaaacatcac agcccggatt ggcgagccac tggtgctgaa gtgtaagggg
120gcccccaaga aaccacccca gcggctggaa tggaaactga acacaggccg
gacagaagct 180tggaaggtcc tgtctcccca gggaggaggc ccctgggaca
gtgtggctcg tgtccttccc 240aacggctccc tcttccttcc ggctgtcggg
atccaggatg aggggatttt ccggtgcagg 300gcaatgaaca ggaatggaaa
ggagaccaag tccaactacc gagtccgtgt ctaccagatt 360cctgggaagc
cagaaattgt agattctgcc tctgaactca cggctggtgt tcccaataag
420gtggggacat gtgtgtcaga gggaagctac cctgcaggga ctcttagctg
gcacttggat 480gggaagcccc tggtgcctaa tgagaaggga gtatctgtga
aggaacagac caggagacac 540cctgagacag ggctcttcac actgcagtcg
gagctaatgg tgaccccagc ccggggagga 600gatccccgtc ccaccttctc
ctgtagcttc agcccaggcc ttccccgaca ccgggccttg 660cgcacagccc
ccatccagcc ccgtgtctgg gagcctgtgc ctctggagga ggtccaattg
720gtggtggagc cagaaggtgg agcagtagct cctggtggaa ccgtaaccct
gacctgtgaa 780gtccctgccc agccctctcc tcaaatccac tggatgaagg
atggtgtgcc cttgcccctt 840ccccccagcc ctgtgctgat cctccctgag
atagggcctc aggaccaggg aacctacagc 900tgtgtggcca cccattccag
ccacgggccc caggaaagcc gtgctgtcag catcagcatc 960atcgaaccag
gcgaggaggg gccaactgca ggctctgtgg gaggatcagg gctgggaact
1020ctagccctgg ccctggggat cctgggaggc ctggggacag ccgccctgct
cattggggtc 1080atcttgtggc aaaggcggca acgccgagga gaggagagga
aggccccaga aaaccaggag 1140gaagaggagg agcgtgcaga actgaatcag
tcggaggaac ctgaggcagg cgagagtagt 1200actggagggc cttgaggggc
ccacagacag atcccatcca tcagctccct tttctttttc 1260ccttgaactg
ttctggcctc agaccaactc tctcctgtat aatctctctc ctgtataacc
1320ccaccttgcc aagctttctt ctacaaccag agccccccac aatgatgatt
aaacacctga 1380cacatcttgc a 13915403PRTMurine 5Met Pro Ala Gly Thr
Ala Ala Arg Ala Trp Val Leu Val Leu Ala Leu1 5 10 15Trp Gly Ala Val
Ala Gly Gly Gln Asn Ile Thr Ala Arg Ile Gly Glu 20 25 30Pro Leu Val
Leu Ser Cys Lys Gly Ala Pro Lys Lys Pro Pro Gln Gln 35 40 45Leu Glu
Trp Lys Leu Asn Thr Gly Arg Thr Glu Ala Trp Lys Val Leu 50 55 60Ser
Pro Gln Gly Gly Pro Trp Asp Ser Val Ala Gln Ile Leu Pro Asn65 70 75
80Gly Ser Leu Leu Leu Pro Ala Thr Gly Ile Val Asp Glu Gly Thr Phe
85 90 95Arg Cys Arg Ala Thr Asn Arg Arg Gly Lys Glu Val Lys Ser Asn
Tyr 100 105 110Arg Val Arg Val Tyr Gln Ile Pro Gly Lys Pro Glu Ile
Val Asp Pro 115 120 125Ala Ser Glu Leu Thr Ala Ser Val Pro Asn Lys
Val Gly Thr Cys Val 130 135 140Ser Glu Gly Ser Tyr Pro Ala Gly Thr
Leu Ser Trp His Leu Asp Gly145 150 155 160Lys Leu Leu Ile Pro Asp
Gly Lys Glu Thr Leu Val Lys Glu Glu Thr 165 170 175Arg Arg His Pro
Glu Thr Gly Leu Phe Thr Leu Arg Ser Glu Leu Thr 180 185 190Val Ile
Pro Thr Gln Gly Gly Thr Thr His Pro Thr Phe Ser Cys Ser 195 200
205Phe Ser Leu Gly Leu Pro Arg Arg Arg Pro Leu Asn Thr Ala Pro Ile
210 215 220Gln Leu Arg Val Arg Glu Pro Gly Pro Pro Glu Gly Ile Gln
Leu Leu225 230 235 240Val Glu Pro Glu Gly Gly Ile Val Ala Pro Gly
Gly Thr Val Thr Leu 245 250 255Thr Cys Ala Ile Ser Ala Gln Pro Pro
Pro Gln Val His Trp Ile Lys 260 265 270Asp Gly Ala Pro Leu Pro Leu
Ala Pro Ser Pro Val Leu Leu Leu Pro 275 280 285Glu Val Gly His Ala
Asp Glu Gly Thr Tyr Ser Cys Val Ala Thr His 290 295 300Pro Ser His
Gly Pro Gln Glu Ser Pro Pro Val Ser Ile Arg Val Thr305 310 315
320Glu Thr Gly Asp Glu Gly Pro Ala Glu Gly Ser Val Gly Glu Ser Gly
325 330 335Leu Gly Thr Leu Ala Leu Ala Leu Gly Ile Leu Gly Gly Leu
Gly Val 340 345 350Val Ala Leu Leu Val Gly Ala Ile Leu Trp Arg Lys
Arg Gln Pro Arg 355 360 365Arg Glu Glu Arg Lys Ala Pro Glu Ser Gln
Glu Asp Glu Glu Glu Arg 370 375 380Ala Glu Leu Asn Gln Ser Glu Glu
Ala Glu Met Pro Glu Asn Gly Ala385 390 395 400Gly Gly Pro
61348DNAMurine 6gcaccatgcc agcggggaca gcagctagag cctgggtgct
ggttcttgct ctatggggag 60ctgtagctgg tggtcagaac atcacagccc ggattggaga
gccacttgtg ctaagctgta 120agggggcccc taagaagccg ccccagcagc
tagaatggaa actgaacaca ggaagaactg 180aagcttggaa ggtcctctct
ccccagggag gcccctggga cagcgtggct caaatcctcc 240ccaatggttc
cctcctcctt ccagccactg gaattgtcga tgaggggacg ttccggtgtc
300gggcaactaa caggcgaggg aaggaggtca agtccaacta ccgagtccga
gtctaccaga 360ttcctgggaa gccagaaatt gtggatcctg cctctgaact
cacagccagt gtccctaata 420aggtggggac atgtgtgtct gagggaagct
accctgcagg gacccttagc tggcacttag 480atgggaaact tctgattccc
gatggcaaag aaacactcgt gaaggaagag accaggagac 540accctgagac
gggactcttt acactgcggt cagagctgac agtgatcccc acccaaggag
600gaaccaccca tcctaccttc tcctgcagtt tcagcctggg ccttccccgg
cgcagacccc 660tgaacacagc ccctatccaa ctccgagtca gggagcctgg
gcctccagag ggcattcagc 720tgttggttga gcctgaaggt ggaatagtcg
ctcctggtgg gactgtgacc ttgacctgtg 780ccatctctgc ccagccccct
cctcaggtcc actggataaa ggatggtgca cccttgcccc 840tggctcccag
ccctgtgctg ctcctccctg aggtggggca cgcggatgag ggcacctata
900gctgcgtggc cacccaccct agccacggac ctcaggaaag ccctcctgtc
agcatcaggg 960tcacagaaac cggcgatgag gggccagctg aaggctctgt
gggtgagtct gggctgggta 1020cgctagccct ggccttgggg atcctgggag
gcctgggagt agtagccctg ctcgtcgggg 1080ctatcctgtg gcgaaaacga
caacccaggc gtgaggagag gaaggccccg gaaagccagg 1140aggatgagga
ggaacgtgca gagctgaatc agtcagagga agcggagatg ccagagaatg
1200gtgccggggg accgtaagag cacccagatc gagcctgtgt gatggcccta
gagcagctcc 1260cccacattcc atcccaattc ctccttgagg cacttccttc
tccaaccaga gcccacatga 1320tccatgctga gtaaacattt gatacggc
1348724DNAArtificialSynthetic PCR Primers 7agcggctgga atggaaactg
aaca 24822DNAArtificialSynthetic PCR Primers 8ctaccacacg ggaacgggga
ag 22930DNAArtificialSynthetic PCR Primers 9gacaagtatc tcgagacacc
tggggatgag 301029DNAArtificialSynthetic PCR Primers 10ccatgctttt
aggttggatg ttcaagaaa 29
* * * * *